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Abstract 
Dementia is a neurodegenerative disease that involves progressive cognitive and functional 
decline. Symptoms vary and commonly include behaviour and psychological disturbances that can 
result in patients being prescribed antipsychotic medications. The use of these medications in 
managing the behavioural and psychological symptoms of dementia is controversial and have been 
the subject of numerous safety warnings. Research has consistently shown that high numbers of 
patients with dementia are still being prescribed antipsychotic medications despite these warnings 
and that there is a significantly higher rate of death for these individuals, compared to those who 
were not taking this type of medication. 
Through descriptive statistics and generalized linear mixed modelling this study aimed to 
show the nature of antipsychotic medication use in Canadian complex and long-term care facilities, 
as well the effects these medication have on various areas of functioning, health, and death rates in 
those with dementia. Approximately 40% of those diagnosed with dementia in Canadian care 
facilities are prescribed antipsychotic medications. Contrary to earlier studies, there was actually a 
slightly lower death rate for those individuals’ prescribed antipsychotic medications daily but a 
significantly higher death rate for those who were taking this form of medication inconsistently (1 to 
6 days a week). These results suggest that there may be fundamental differences between the 
individuals receiving antipsychotic medications as a PRN and those who received them everyday, or 
that medical professionals and caregivers should ensure that patients with dementia consistently take 
antipsychotic medication, if required, rather than prescribing it on an as needed basis. Future 
research into the differences in death rate based on the frequency of antipsychotic medication use 
would be highly beneficial to confirm these findings, which contradict past research, to provide 
further insight into the safety of these medications for older adults with and without dementia. 
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The effects of antipsychotic medications on older adults with dementia in 
Canadian complex and long-term care facilities 
Dementia 
Dementia is a neurodegenerative disease caused by a variety of illnesses that involves 
progressive cognitive and functional decline. Symptoms of dementia vary between people but 
they typically include memory impairment with diminished capacity in other areas such as 
reasoning, communication skills, the ability to complete activities of daily living (ADL), and in 
the development of behavioural and psychological symptoms (BPSD). Dementia is an 
irreversible progressive syndrome with symptoms starting gradually and becoming more 
numerous and intense over time. 
Causes 
Dementia is caused by structural and chemical changes in the brain resulting in the death 
of brain tissue. There are many illnesses that can cause dementia by damaging different parts of 
the brain while inducing relatively similar symptoms. Alzheimer’s disease is the most well 
known and common cause of dementia and accounts for 63% of all dementias in Canada 
(Alzheimer Society of Canada, 2010). Alzheimer’s disease is due to a deficiency in 
acetylcholine neurotransmitters (Neef & Walling, 2006), which causes the parieto-temporal 
regions, including the hippocampus and surrounding cortical structures of the brain, to atrophy 
(Braaten, Parsons, McCue, Sellers & Burns, 2006). The second most common form of dementia, 
vascular dementia, is caused by issues related to heart disease, including strokes, high blood 
pressure, endocarditis, and brain aneurisms. Vascular dementia is relatively unique in that the 
root cause of the dementia is highly variable and dependent on where the lesion or clot occurs in 
Antipsychotic Medications and Dementia 3 
the brain (Cummings & Benson, 1992). However it is generally primarily cortical, subcortical, 
or a combination of both (Braaten et al., 2006). 
Fronto-temporal dementia is caused by a degeneration of the frontal and anterior 
temporal lobes (Braaten et al, 2006), while dementia due to multiple sclerosis is related to 
atrophy in deep grey matter and the mesial temporal lobe (Benedict, Ramasamy, Munschauer, 
Weinstock-Guttman & Zivadinov, 2009). Parkinson’s disease can also cause dementia due to 
the death of dopamine generating cells in the pars compacta region of the substantia nigra 
(Obeso et al., 2008). The death of these cells has been shown to cause a loss of gray matter in 
the temporal, occipital, and subcortical regions of the brain (Burton, McKeith, Bum, Williams & 
O'Brien, 2004). In addition, Lewy bodies, eosinophilic cytoplasmic inclusions that contain 
deposits of a protein called alpha-synuclein, develop in the brain in Parkinson’s disease resulting 
in further damage and dementia symptoms. Contrasting dementia due to Parkinson’s, dementia 
with Lewy bodies is caused by the development of Lewy bodies in the subcortical and cortical 
areas of the brain, as well as amyloid plaques (McKeith et al., 2004), without the further 
pathology related to Parkinson’s disease. 
Several additional forms of dementia are the result of disease or injury to white matter in 
the brain. Typically the diseases or injuries that affect white matter in the brain are diffuse or 
multifocal and cause dementia rather than specific cognitive deficits or behavioural issues (Rao, 
1996). Some of the causes of dementias related to cerebral white matter are: multiple sclerosis, 
due to demyelination and white matter lesions; acquired immune deficiency syndrome (AIDS), 
caused by issues such as generalized atrophy, areas of myelin pallor, and patches of 
demyelination; traumatic brain injury, due to axonal shearing, or broad axonal injury, that causes 
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ventricular enlargement and atrophy of white matter; and alcoholic dementia, caused by heavy 
long-term drinking which damages white matter through toxicity (Rao, 1996). 
Demographics 
In 2008, it was estimated that approximately 480,600 people in Canada suffered from 
some form of dementia, with an annual incidence rate of 103,700 (Alzheimer Society of Canada, 
2010). The risk of developing dementia increases with age, with less than 1% of Canadians 
under 65 suffering from dementia compared to 2.5% of people between 65 and 74 years of age, 
and increasing to 35% for those over 85 years of age (Canadian Study of Health and Aging 
Working Group, 1994). As the oldest of the large 9.9 million Canadian baby-boomer (those bom 
between 1947-1966) generation are starting to turn 65 years of age this year, this cohort is 
beginning to enter the age range of greatest risk for developing dementia (Forbes & Neufeld, 
2008). It is estimated that within the next 25 years the number of new cases of dementia in 
Canadians 65 years of age and older is expected to increase by 2.5 times, leading to the diagnosis 
of 257,800 new dementia patients annually. This will bring the estimated total number of 
Canadians suffering with dementia to a staggering 1,125,200, the equivalent of about 2.8% of the 
Canadian population (Alzheimer Society of Canada, 2010). 
With the significant increase in the numbers of people being diagnosed with dementia in 
Canada over the next 25 years, dementia related care requirements are expected to soar as well. 
The need for long-term care beds is expected to increase from 280,000 in 2008, to 690,000 in 
2038 (Alzheimer Society of Canada, 2010). Unfortunately, many of the people needing long- 
term care beds will not have access to them due to projected shortfalls of availability. These 
individuals will be forced to reside in the community under the care of their family or hired 
caregivers. The number of hours spent caring for people with dementia in the community by 
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informal caregivers (e.g. family, friends) is expected to more than triple in the same time period 
to 756 million hours per year. Economically, the cost of caring for people with dementia is 
expected to increase from $15 billion in 2008, to an incredible $153 billion in 2038, taking 
inflation into account. 
Symptoms 
Pre-clinical dementia. Pre-clinical dementia is generally defined as the period of five 
years prior to formal diagnosis with dementia (Ramakers et al., 2007). It is during this period of 
time that physical, cognitive, and behavioural symptoms begin to become noticeable but are not 
significant enough to be diagnosable as dementia. During this time an individual may be 
diagnosed with mild cognitive impairment, meaning that he or she is showing signs of cognitive 
decline along a continuum between a normal elderly person and one with clear dementia 
(Fratiglioni, Grut, Forsell, Viitanen & Winblad, 1992). Increased visits to family physicians are 
common (Wilkinson, Stave, Keohane & Vincenzino, 2004), with a significant increase of 
medical visits within the two years prior to diagnosis (Ramakers et al., 2007). 
In a review of pre-diagnosis medical records of 74 patients with dementia and 125 non- 
demented controls it was found that the earliest predictor of dementia is gait disturbances 
(Ramakers et al., 2007). This symptom was predictive of dementia five years before diagnosis. 
Cognitive complaints, especially regarding memory issues, became predictive of dementia two 
years before formal diagnosis. Other research studies have shown that there is a strong 
relationship between gait and cognition, as well as gait-related motor disturbances and dementia 
(Scherder et al., 2007; Scherder, Eggermont, Visscher, Scheltens, Swaab, 2011; Waite, Grayson, 
Piguet, Creasey, Bennet & Broe, 2005). BPSD only appeared approximately one year prior to 
diagnosis (Ramakers et al., 2007). The researchers of this study hypothesize that the BPSD 
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symptoms develop later in the neurodegenerative process or only became severe enough to start 
reporting to the family physician in the year prior to diagnosis. 
Cognitive symptoms. Cognitive symptoms of dementia are highly variable between 
individuals, including individuals who are suffering from the same form of dementia, and as a 
result there are two principles that form the concept of dementia (Knopman, Boeve & Petersen, 
2003). The first principle is that the person suspected of suffering from dementia has experienced 
a decline from some form of previously higher level of functioning. This decline has to be above 
and beyond what would be considered normal aging such as an increase in forgetfulness greater 
than what would be typical for others of the same age. The second principle is that the 
symptoms of the suspected dementia significantly interfere with ADL such as work or social 
activities. 
There are five main cognitive areas that may be impaired to a varied degree in those 
people suffering from dementia. They include: memory, language, apraxia, agnosia, and 
executive functioning (American Psychiatric Association [DSM-FV-TR], 2000). Memory 
impairment is a requirement for the diagnosis of all dementias and is usually one of the first 
apparent symptoms. Dementia may cause a decline in the ability to learn, retain, and retrieve 
newly learned information (Knopman, Boeve & Petersen, 2003), or may negatively impact the 
person’s remote memory which includes the ability to recall personal information as well as 
information learned historically (American Psychological Association, 2000). The degree and 
nature of memory impairment in a person with dementia may help differentiate between which 
form of dementia he or she are suffering from. For example, in Alzheimer’s disease, the most 
obvious symptom is typically pervasive forgetfulness which may include paying bills, repeating 
questions because the person has forgotten that the question has been asked and answered, 
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geographic disorientation, and lapses in judgement (Knopman, Boeve & Petersen, 2003). In 
contrast, memory is relatively preserved in frontotemporal dementia to the point where these 
patients may score in the normal range in tests of delayed recall. 
Impairment in language function causes decline in the ability to comprehend and express 
verbal information (Knopman, Boeve & Petersen, 2003). Patients may develop aphasia 
(difficulty producing the names of people and objects), echolalia (echoing what they hear), 
and/or palilalia (continuous repetition of sounds or words) (American Psychological Association, 
2000). In addition, the individual suffering from dementia may have impairment in 
comprehension of spoken and written language. 
Apraxia (reduction in ability to complete physical tasks despite intact motor abilities, 
sensory function, and understanding of the desired task) is another cognitive area that may be 
compromised due to dementia (American Psychological Association, 2000). Individuals with 
apraxia may have difficulty completing activities such as picking up a mug, brushing their teeth, 
or getting dressed. Agnosia is defined as the inability to recognize or identify objects even 
though sensory function is intact (American Psychological Association, 2000). For people with 
agnosia, the ability to recognize everyday objects, is impaired which may progress into the 
inability to recognize love ones or themselves. 
Problems with executive functioning are present when a person has impairment in the 
ability to perform higher-order functioning such as abstract reasoning, problem-solving, mental 
manipulation of more than one idea at a time, and maintaining mental focus (Knop, Boeve & 
Petersen, 2003). The Diagnostic Statistical Manual of Mental Disorders (DSM)(2000) describes 
executive functioning as, “... the ability to think abstractly and to plan, initiate, sequence, 
monitor, and stop complex behavior” (p. 149). 
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Cognitive symptoms of dementia develop at a varied pace based on the individual as well 
as the cause of the dementia. Cognitive symptoms may be present at least two years prior to 
diagnosis (Ramakers et al., 2007) although patients may not express cognitive complaints until 
much later (Ganguli et al., 2006). This may be due to patients feeling ashamed and therefore not 
reporting their cognitive symptoms or patients assuming that their cognitive impairment is 
normal for their age. Alternatively, patients may be unaware of their cognitive symptoms 
(Ramakers et al., 2007). Rate of decline may occur slowly, as in some cases of Alzheimer’s 
disease, or progress rapidly, as seen in non-vasculitic autoimmune inflammatory 
meningoencephalopathies such as Hashimoto encephalopathy (Knopman, Boeve & Petersen, 
2003). Women, and those with more education, have been shown to have more rapid decline in 
cognitive functioning and older age has been shown to be predictive of greater cognitive and 
functional impairment (Tschanz et al., 2011). 
Behavioural and psychological symptoms. Alois Alzheimer described behavioural and 
psychological disturbances prominently in his original case study of the disease, subsequently 
named after him, in the early twentieth century (Alzheimer, 1906). Alzheimer described the 
subject of his case study as suffering from paranoia, delusions of sexual abuse, hallucinations, 
and screaming. While BPSD was a focus of this case study, research on the cognitive factors 
related to dementia dominated the field for many years. In the early 1980s research on BPSD 
began to increase substantially (International Psychogeriatric Association, 2002). 
In 1996 the International Psychogeriatric Association (IPA) convened a Consensus 
Conference on the behavioural disturbances of dementia. The Consensus group consisted of 
approximately 60 experts in the dementia field from 16 different countries (Kozman, Wattis & 
Curran, 2006). They created a definition of BPSD to increase consistency within future research 
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that stated, “the term behavioral disturbances should be replaced by the term behavioral and 
psychological symptoms of dementia (BPSD), defined as; Symptoms of disturbed perception, 
thought content, mood or behavior that frequently occur in patients with dementia”. The 
consensus group also acknowledged that it may be helpful to group specific symptoms into 
clusters, such as behavioural symptoms and psychological symptoms, to aid in research, which is 
how BPSD will be described below. 
Behavioural symptoms. Behavioural symptoms of dementia include all physical and 
verbal symptoms displayed by a person suffering from the disease. 
Agitation and aggression. Agitation is a state of psychological and physical restlessness, 
and can manifest as behaviours such as pacing, general irritation, and repetitive actions such as 
nail biting or skin picking. Aggression includes acts of verbal and physical abuse towards 
others, including acts such as threats of assault, physical violence, emotional abuse, verbal sexual 
harassment, and sexual assault (Bostrom, Squires, Mitchell, Sales & Estabrooks, 2011). 
Aggression commonly results from agitation and therefore the two are routinely combined in 
research (International Psychogeriatric Association, 2002; Lovheim, Sandman, Karlsson, & 
Gustafson, 2009; Lyketsos, Steinberg, Tschanz, Norton, Steffens, & Breitner, 2000). 
Agitation and aggression are two of the most significant behavioural symptoms in 
dementia, occurring in between 20% to 50% of patients (International Psychogeriatric 
Association, 2002; lost & Grossberg, 1996; Lyketsos et al., 2000). Among restless behaviours, it 
has been shown that women are more likely to roll up table cloths, while men will more 
commonly stack or overturn chairs and other furniture (Lovheim et al., 2009). In regards to 
restless wandering, women are more likely to hide things than men, while men more frequently 
stand at an outside door wanting to go out. Aggressive behaviours, such as hitting others. 
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making violent threats, resisting being dressed or undressed, and becoming easily annoyed, are 
more common among men. Agitation and aggressive behaviour typically peak in the middle 
stages of dementia, and reduction in these behaviours later in the disease is hypothesized to be 
due to reduced language and communication ability, as well as restricted motor functions 
(Lovheim et al., 2008). 
Verbally disruptive and attention seeking. Verbally disruptive and attention seeking 
behaviours can add significant stress and pressure on caregivers and loved ones. These types of 
behaviours can include symptoms such as constantly seeking the attention and/or help of staff, 
repeated complaining, continuously shrieking or shouting (Lovheim et al., 2009), moaning, and 
wailing (Runci, Redman & O’Connor, 2006). Attention seeking behaviour occurs in 40% to 
52% of dementia patients living in long-term care facilities (Lovheim et al., 2008). The different 
behaviours are consistent between men and women, however, women are more likely to exhibit 
help seeking behaviours and make complaints (Lovheim et al., 2009). This gender difference 
may occur due to higher rates of depression diagnosis in women with dementia which leads them 
to seek support and complain. 
Verbally disruptive behaviour is observed in 12-50% of patients with dementia in long- 
term care facilities (Bourbonnais & Ducharme, 2010). It has been found that people who scream 
due to dementia have higher levels of depression, are more prone to falling, are more often 
restrained, have lower cognitive functioning, less autonomy, and have a poorer social network 
than patients who do not scream (Cohen-Mansfield, Werner & Marx, 1990; Cohen-Mansfield, 
Marx & Werner, 1992). Verbally disruptive behaviour in dementia patients is said to be due to 
the person residing in a state of confusion because they continue to live in a highly cognitive 
world but no longer have the capacity to interpret it (Boubannais & Ducharme, 2010). This can 
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make the external world very confusing and frightening, which can lead some people with 
dementia to express themselves with verbally disruptive behaviour, purposefully or not. It has 
been found that screams (and other disruptive behaviour) can express seven different factors 
such as dissatisfaction or satisfaction, pain, emotions, physical needs, desire to modify 
environment, and enigmatic (Burbannais & Ducharme, 2010). No significant gender differences 
have been found for this behaviour between men and women. 
Inappropriate and regressive. Inappropriate and regressive behaviour includes 
behaviours such as being unruly in bed; urinating in inappropriate places such as wastebaskets, 
wash basins, and on the floor; smearing feces on clothing, walls, and furniture; laying in other 
peoples beds; taking other people’s possessions; and undressing in public rooms (Lovheim et al., 
2009). These behaviours may occur for several reasons including confusion, poor memory, 
disinhibition, or lack of judgement. Inappropriate and regressive behaviour occurs in 7% to 21% 
of dementia patients in long-term care facilities (Lovheim et al., 2008). Research shows that 
these symptoms are more common in men than in women, with the exception of undressing in 
public rooms and smearing feces where there is equal prevalence (Lovheim et al., 2009). 
Sexual. Sexual disinhibition can be difficult for caregivers, families, and medical 
practitioners to manage, causing distress and embarrassment. Sexually inappropriate behaviours 
have been divided into two types: intimacy seeking and disinhibited (de Medeiros, Rosenberg, 
Baker & Onyike, 2008). Intimacy seeking consists of normal behaviours that are misplaced in 
social context (e.g. kissing, hugging). Disinhibited behaviour consists of rude and intrusive 
behaviours that would be considered inappropriate in most contexts (e.g. fondling, 
exhibitionism). Dealing with inappropriate sexual behaviour can be a difficult issue in care 
facilities. There is a need to respect the patient’s sexuality and understand that he or she is still a 
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sexual being, while trying to balance the emotional and physical safety of other patients, family 
members, and staff. Unfortunately, the line between respect and safety is often very blurry. 
Occurrence of inappropriate sexual behaviours varies dramatically depending on the 
setting, ranging from estimates of 1.8% to 25%, with it being more common in higher-level care 
(Tucker, 2010). It has been shown that Alzheimer’s disease is associated with intimacy seeking 
behaviours while non-Alzheimer’s dementia is associated with disinhibited behaviours (de 
Medeiros et al., 2008). The majority of the people who exhibit these behaviours are men who 
frequently have other conditions contributing to their dementia such as subdural hemorrhage or 
long-standing alcoholism (Tucker, 2010). It has also been found that there is an over- 
representation of men who engage in sexually inappropriate behaviours that have early onset 
dementia between 40 and 60 years of age. 
Psychological symptoms. Psychological symptoms of dementia include all mental and 
emotional symptoms displayed by a person suffering from the disease. 
Personality changes. As many as 90% of people diagnosed with dementia experience 
changes in their personality (International Psychogeriatric Association, 2002). Approximately 
half of the people who develop dementia, or have the neurological markers of Alzheimer’s 
disease at autopsy, experience personality change prior to diagnosis (Balsis, Carpenter & 
Storandt, 2005). In comparison, less than one quarter of seniors who do not develop dementia 
experience personality change prior to death. In a study by Balsis et al., (2005), it was found that 
people became increasingly self-centred and inflexible before their diagnosis of dementia. Some 
people also became increasingly withdrawn and apathetic, while others became more impulsive 
and emotionally labile. 
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Throughout the course of dementia, common personality changes based on the five-factor 
model of personality (Costa & McCrae, 2002) include increased neuroticism while extroversion, 
openness, and conscientiousness decreased (Siegler, Dawson & Welsh, 1994). Other studies 
have looked at personality change in dementia based on the Blessed Dementia Scale (Blessed, 
Tomlinson & Roth, 1968). This scale identifies changes in the person’s personality, drives, and 
interests. It has been found that people with dementia are frequently rigid and self-centred, lack 
concern for others, and display rigidity of affect (Bozzola, Gorelick & Freels, 1992). Balsis et 
al., (2005) summarized his study by saying that people with dementia change in negative ways 
relative to their former selves and become more erratic, passive, aloof, withdrawn, rash, and 
immature. 
Apathy. Apathy in dementia is characterized by a lack of initiative (Ldvheim et al., 2009) 
and motivation that is not due to diminished level of consciousness, cognitive impairment, or 
emotional distress (Marin, 1991). Depending on the individual, apathy can cause patients to no 
longer talk spontaneously, cooperate with others, and to not enjoy previously enjoyed activities 
(Lovheim et al., 2009). Prevalence estimates of apathy in community dwelling individuals with 
dementia are between 17% and 37% (Onyike et al., 2007). Estimates drastically increase for 
individuals living in long-term care facilities with prevalence rates estimated up to 80% 
(Lovheim et al., 2008). Gender is not correlated with apathy (Lovheim et al., 2009), and while it 
does not affect cognitive decline, apathy is significantly correlated with functional decline 
(Clarke, Ko, Lyketsos, Rebok & Eaton, 2010). It has been shown that apathy is the only BPSD 
that becomes continually worse throughout the progression of dementia, until the patient dies 
(Ldvheim et al., 2008), 
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Depression. Depression is a serious psychological symptom of dementia. It can cause 
sadness, loss of interest, weakness and fatigue, sleep difficulties, agitation, and feelings of 
worthlessness or guilt. Depression can also cause an alteration in eating habits and non- 
purposeful fluctuations in weight. When severe, it can make the individual want to die and/or 
consider suicide (Park et al., 2007). While depression can be very difficult for the individual 
with dementia to deal with, caregivers also experience a negative impact from these symptoms 
which can lead to early institutionalization for the dementia patient (Teri & Wagner, 1992). 
There is much debate regarding the nature of depression in dementia. Some say that 
depression is a risk factor for dementia (Mondrego & Ferrandez, 2004; Andersen, Lolk, Kragh- 
Sorensen, Petersen & Green, 2005), while others have shown that depression and its symptoms 
are actually part of a prodromal phase of dementia and therefore not a risk factor (Vinkers, 
Gussekloo, Stek, Westendorp & Van Der Mast, 2004; Ganguli, Du, Dodge, Ratcliff & Chang, 
2006). Depression is more common in people with dementia than those without dementia 
(Lovheim et al., 2008; Bergdahl, Allard & Gustafson, 2011). Up to 80% of individuals with 
dementia are said to suffer from depression during the course of their illness (International 
Psychogeriatric Association, 2002), with more significant depressive symptoms in the early and 
middle stages of the disease, and reducing in the later stages when there is more severe cognitive 
impairment (Lovheim et al., 2008). Some studies have shown that there is a difference in 
prevalence rates of depression between vascular dementia and Alzheimer’s disease, with 
vascular dementia having significantly higher rates (Park et al., 2007). Other studies have found 
that there are no differences in rates of depression between forms of dementia (Thompson, 
Brodaty, Trollor & Sachdev, 2010). Depression in dementia has been shown to be significantly 
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more common in women, which is consistent with life-time prevalence rates of depressive 
disorders (Ldvheim et al., 2009). 
Anxiety. Anxiety involves apprehensive expectation and worry (Smith et al., 2008), and 
may include symptoms of restlessness, being easily fatigued, difficulty concentrating, irritability, 
muscle tension, and sleep disturbances (American Psychological Association, 2000), as well as 
suspiciousness (Ferretti, McCurry, Logsdon, Gibbons & Teri, 2001). Anxiety in dementia can 
be explained through the Progressively Lowered Stress Threshold model (PLST) (Hall & 
Buckwalter, 1987). PLST posits that dementia related anxiety is increased due to confusing or 
overwhelming aspects of the physical and social environment, overstimulation, physical illness, 
and demands that exceed the individual’s ability to function. This model suggests that anxiety 
signals the onset of more intense and challenging behaviours that increase the risk of behavioural 
incidents. These incidents may promote the unnecessary use of medications to manage the 
behaviour and increase the potential that the individual is moved to a higher level of care (Smith 
et al., 2008). 
Prevalence rates for anxiety in individuals with dementia are conservatively estimated to 
be 35% (Seignourel, Kunik, Snow, Wilson & Stanley, 2008). Anxiety symptoms appear to be 
stable throughout the course of dementia, until the later stages when impairment is profound. In 
regards to differences in anxiety between dementia types, anxiety appears to be greater in 
vascular dementia than in Alzheimer’s disease (Seignourel et al., 2008), as well as 
frontotemporal dementia (Porter et al., 2003) and dementia associated with Parkinson’s disease 
(Aarsland Cummings & Larsen, 2001). Dementia related anxiety has been shown to cause poor 
quality of life which includes more functional limitations, poor physical health, and reduced 
activities, after controlling for depression, problem behaviours, and dependency (Hoe, Hancock, 
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Livingston & Orrell, 2006). Unmet needs, including laek of daytime activities, psychological 
distress, lack of company, and memory and communication problems, have been associated with 
higher levels of anxiety in individuals with dementia living in long-term care facilities (Hancock, 
Woods, Challis & Orrell, 2006). It does not appear that there is a gender difference in anxiety 
levels in individuals with dementia (Mendez et ah, 2006), which contrasts with the finding that 
anxiety symptoms and disorders are more common in women amoung those not suffering from 
dementia (Stanley & Beck, 2000). 
Delusions. A delusion is defined as a false belief, based on ineorrect beliefs and 
assumptions about an external reality, which is firmly held despite what most people believe and 
despite undeniable evidence and obvious proof to the contrary (American Psychological 
Association, 2000). Common delusions associated with dementia include delusions of theft, 
abandonment, danger, ‘one’s house is not one’s home’ (where an individual believes that their 
house is not theirs), misidentification, infidelity, and non-paranoid delusions (Fischer, 
Bozanovic-Sosic & Norris, 2004). Delusions regarding theft and ‘one’s house is not one’s home’ 
are the most commonly experience delusions, followed by delusions related to suspiciousness 
and abandonment (Shaji, Bose & Kuriakose, 2009). 
Delusional symptoms are commonly associated with the individual being disoriented 
regarding time, physical location, and other people (Cohen-Mansfield, Colander, Ben-Israel & 
Garfinkel, 2011). For example, in a ‘one’s house is not one’s home’ delusion, the individual 
may not reeognize the nursing home they are in or may not remember actually moving into a 
nursing home. Loneliness and insecurity can influence delusions of abandonment, which may 
cause individuals with dementia to believe that their families have left them or that they have no 
one that loves them. Boredom is a risk factor for increased delusional symptoms. It has been 
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found that delusions are more common when there are no activities occurring or when an 
individual is looking for stimulation. Other common triggers for delusions can be environmental 
phenomena including not being able to find an object, watching the news, staff shift change, 
talking about the past, and people going in and out of care facilities with bags. 
Delusions occur in an estimated 20% to 73% of individuals with dementia (International 
Psychogeriatric Association, 2002). Those with Alzheimer’s disease have delusions more often 
than people with vascular dementias (Lyketsos et al., 2000). Individuals with poor vision, or 
who are blind, have significantly more delusions regarding theft, abandonment, and danger, than 
those with minor or no vision problems (Cohen-Mansfield et al., 2011). Delusions are not a 
significant predictor of mortality, but are associated with greater cognitive and functional decline 
and institutionalization rates (Scarmeas et al., 2005). 
Hallucinations. Hallucinations are perceived sensory experiences that an individual 
believes are real, when these experiences are not, or have not, actually occurred (American 
Psychological Association, 2000). Hallucinations can occur in any sensory modality, but visual 
hallucinations are the most common in dementia. Hallucinations are believed to be caused by 
the activation of specific cortical areas, due to damage in the brain associated with the dementia, 
related to the specific hallucination (Howard et al., 1997). For example, hallucinations of faces 
are accompanied by the activation of cortical areas involved in face perception on magnetic 
resonance imaging. While auditory hallucinations are more common than visual hallucinations 
in other psychotic disorders (American Psychological Association, 2000), auditory hallucinations 
rarely occur without a concurrent visual hallucination in patients with dementia (Inzelberg, 
Kipervasser & Korczyn, 1998). 
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It has been reported that 15% to 49% of people with dementia suffer from hallucinations 
(International Psychogeriatric Association, 2002). Hallucinations can be either simple or 
complex (Mosimann et al., 2006). Simple hallucinations include flashes, dots, or grids, while 
complex hallucinations are well formed typically of people, animals, or objects. Simple 
hallucinations in isolation are rare; rather it is more common for people with dementia to 
experience complex visual hallucinations (Mosimann et al., 2006). Hallucinations are more 
common in dementia due to Parkinson’s disease, as well as dementia with Lewy bodies, than 
other forms of dementia (Lovheim et al., 2008). This is due to the nature of damage caused by 
Lewy bodies in the brain in these two forms of dementia. As with most other BPSD, 
hallucination symptoms tend to be most severe during moderate dementia and decrease at later 
stages of dementia when the individual has severe cognitive impairment (Lovheim et al., 2008). 
Prevalence of auditory and visual hallucinations are equal for both males and females (Lovheim 
et al., 2009). 
Impact of Behavioural and Psychological Symptoms 
Families and other caregivers. Quite often, family members may know the formal 
diagnosis of their loved ones’ dementia, before the individual knows themselves. A doctor might 
discuss the diagnosis of dementia with a direct family member in order to ascertain the best way 
to go about informing the patient. Bamford et al., (2004) revealed that one third to two thirds of 
medical practitioners have difficulty revealing the diagnosis of dementia to their patients. Their 
study also showed that family members are reluctant to disclose the diagnosis of dementia to 
their loved one, due to fear of causing emotional stress, the stigma associated with dementia, and 
questions regarding the ability of the individual to understand and remember the diagnosis. If 
the individual with dementia does not possess positive coping skills or the ability to deal with 
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their diagnosis for whatever reason, BPSD may increase directly affecting those around them 
(Aminzadeh et al., 2007). 
Family members typically become the primary caregivers, providing up to 90% of in- 
home care for people with dementia (Keating, Fast, Frederick, Cranswick & Perrier, 1999). 
Because BPSD are a major cause of distress for caregivers, and dementia is recognized as one of 
the hardest illnesses to care for, caregivers of people with dementia are at extremely high-risk to 
suffer from burn-out (Canadian Institute for Health Information; CIHI, 2010). BPSD plays a 
major role in the risk of burn-out, which occurs when caregivers are physically, mentally, and 
emotionally depleted from caring for another person (Pinquart & Sorensen, 2004). Burn-out, and 
simply the stress of caring for an individual with dementia, may cause caregivers to suffer 
symptoms such as decreased personal health, injury, depression, anxiety, fatigue, financial 
problems, and employment losses (Lilly, Robinson, Holtzman & Bottorff, 2012). 
Caring for an individual with dementia is very demanding work, even when burn-out is 
not present. Research has shown that caregivers often feel taken for granted by healthcare 
providers and the health care system, other family members, as well as the individual with 
dementia himself/herself (Lilly et al., 2012). Caregivers in Canada feel that they do not receive 
enough support from professionals to help care for their loved ones, and that the availability for 
respite and relief services is lacking (Lilly et al., 2012). When caregivers are tired and feeling 
overwhelmed, they may become reactionary to the individual with dementia (Pulsford & 
Duxbury, 2006). This can increase the risk for elder abuse and neglect. 
While it is a difficult decision to make, when the family caregivers become burnt out 
from caring for a loved one with significant symptoms due to dementia, they are typically forced 
to place the individual in long-term care (CIHI, 2010). BPSD are commonly cited by caregivers 
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as one of the primary reasons for the institutionalization of their relative (International 
Psychogeriatric Association, 2002). This is often the time when BPSD are very disruptive and 
may cause safety concerns for the individual with dementia and/or their caregivers (Logsdon, 
McCurry & Teri, 2007). 
Individuals with dementia. By the time of dementia diagnosis, cognitive decline and 
BPSD tend to be easily observed by others (Ramakers et al., 2007). In some cases, the 
individual with dementia is also aware that they are going through cognitive and behavioural 
changes (Aminzadeh, Byszewski, Molnar & Eisner, 2007). When individuals are formally 
diagnosed, they not only have to deal with the impending losses associated with a disabling and 
terminal illness, but they will also have to deal with the stigma that comes with the label 
‘dementia’ (Harman & Clare, 2006). Powerful emotional reactions are associated with the 
diagnosis of dementia, including fear of stigma and devaluation, mourning associated with actual 
and anticipated losses, and a sense of increased vulnerability of self (Aminzadeh et al., 2007). 
This is especially the case with Alzheimer’s disease, presumably due to the negative stereotypes 
associated with the disease, as well as the well-known devastation it causes. Limited research 
has shown that emotional and behavioural reactions to the diagnosis of dementia, and the threat 
of destruction of self, may have a more significant impact on the disease outcomes than the 
actual cognitive changes (Bryden, 2002). 
Quality of life (QOL) assessments have been used to measure the subjective perception 
of quality of life in those with dementia, their family, and caregivers (International 
Psychogeriatric Association, 2002). These assessments measure the individual’s health status, 
including health associated disabilities; environment, including restrictions, stigma, opportunity 
for choice; subjective perceptions of mood, physical discomfort, and frustration; other’s 
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observations of activity, affect, and social involvement; and caregiver’s report of mood and 
behaviour. A recent study that looked at QOL ratings in dementia patients also looked at what 
family and paid caregivers would rate the QOL for the individual with dementia (Crespo, 
Bemaldo de Quiros, Gomez & Hornillios, 2012). It was found that the individuals with dementia 
believe they have a better quality of life than did their family or caregivers, which was seen in 
factors such as mood, yourself overall, life overall, energy, relationship with family, and 
relationship with friends. Paid caregivers gave the second highest QOL rating, with family 
giving the poorest. This may be due to the fact that the family has been able to witness the full 
decline of the individual with dementia, and the patient themself has either mentally 
accommodated their circumstances, or has lost insight into their full situation. 
The individual with dementia will need increased care and support in order to complete 
ADL and function day to day. When BPSD are present, most can be deemed disruptive and 
cause psychological distress to those around them (Pinquart & Sorensen, 2004), which may 
cause negative reactions that effect the individual. BPSD can also impact the person with 
dementia by causing earlier long-term care referral and poorer prognosis (Lyketsos et al., 2000). 
When residing in a long-term care facility, BPSD may also cause the individual to be put on 
more medication than those patients without BPSD, as well as be physically restrained (Feng et 
al., 2009). There are many questions surrounding the efficacy of medications used for BPSD, 
and potential health ramifications. 
Management of Behavioural and Psychological Symptoms 
Psychosocial Interventions. Due to the impact that BPSD has on individuals with 
dementia, their families, and caregivers, as well as the often disruptive nature of the symptoms, 
management of BPSD is seen as very difficult and highly important. Psychosocial interventions 
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aimed at the treatment of BPSD in long-term care facilities are being developed as an alternative 
to pharmacological management (Vernooij-Dassen, Vasse, Zuidema, Cohen-Mansfield, & 
Moyle, 2010), but at this point most have been poorly researched. These strategies try to 
improve the quality of life of those with dementia by focusing on the patients’ abilities and 
strengths, while compensating for existing deficits. Psychosocial interventions consist of a wide 
range of approaches, and can focus on training staff who work with individuals with dementia, or 
interventions which can be directed at those with dementia. 
Some of the most promising and researched psychosocial interventions focus on training 
staff who work with people with dementia. It has been found that staff training in long-term care 
facilities can significantly reduce resident behavioural issues, improve communication between 
staff and residents, and improve quality of life indicators for those with dementia. Staff who are 
trained in verbal and non-verbal communication techniques, and are able to recognize potential 
resident needs through behaviour and attitudes, are able to improve staff-resident interactions 
and life satisfaction and reduce behavioural issues and depression (Kuske, Hanns, Luck, 
Angermeyer, Behrens, & Riedel-Heller, 2007; Levy-Storms, 2008; Vasse, Vernooij-Dassen, 
Spijker, Olde-Rikkert, & Koopmans, 2010). 
In 2004, a new approach to managing problematic behaviour related to dementia was 
developed in South Central Ontario and has been implemented in many Ontario and Canadian 
long-term care homes since (Pettit, 2012). The intervention is called the Gentle Persuasive 
Approach (GPA), which reframes how aggressive behaviours in those with dementia are viewed 
by staff in long-term care settings (Speziale, Black, Coatsworth-Puspoky, Ross & O’Regan, 
2009). Instead of focusing on aggressive and disruptive behaviours in relation to neuropathology 
caused by dementia, staff are trained to look at these behaviours occurring as a result of unmet 
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needs, and a way for the individual with dementia to communicate, protect themselves, and re- 
exert control over their lives. GPA teaches that these behaviours may be the only way the 
cognitively impaired individual can deal with a life that has become, or is increasingly becoming, 
unfamiliar and frightening. 
In a study by Speziale et al. (2009), pre and post effectiveness of GPA on aggressive and 
disruptive behaviour was analyzed for the three months immediately proceeding staff training in 
this intervention. Staff was comprised of various professions working with dementia patients in 
a tertiary treatment facility for older adults in Ontario. It was found that over 95% of staff that 
went through GPA training thought the course was very good or excellent, and that they would 
recommend it to coworkers. Approximately 70% of staff reported that GPA was most useful 
with patients who were verbally and physically aggressive. Physical aggression by patients was 
reduced by 50%, with 42 patients being involved in 370 reported aggressive incidents prior to 
GPA training, and 39 patients involved in only 194 incidents after GPA training. In addition, 
staff reported a better understanding of the presenting features of dementia, and that a respectful 
and tolerant approach worked best with the dementia patients. 
There are a few psychosocial interventions, directed at individuals with dementia, which 
have shown potential for reducing BPSD, although research in this area is scant and little is 
known about their true efficacy. Cognitive stimulation therapy (CST), which focuses on issues 
such as mental alertness, orientation, reminiscence, and language and executive functioning 
stimulation, has been shown to help reduce depression with a limited effect on reducing 
behavioural symptoms, in several short term studies (Livingston et al., 2005). One study, with 
201 individuals with dementia recruited from long-term care homes and day treatment centres, 
randomly divided participants into a CST group or treatment as usual. It was found that after 
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eight weeks, there was significant improvement in quality of life in the CST group, with lower 
levels of depression and dependency, and increased cognitive functioning, but no effect on 
behavioural symptoms (Woods, Thorgrimsen, Spector, Royan & Orrell, 2006). 
Behavioural management techniques that focus on an individual patient’s needs have also 
been shown to reduce behavioural symptoms and depression (Livingston et al., 2005). Some 
strategies that have been utilized in these studies have been problem solving techniques, 
progressive muscle relaxations, reminiscence, and positive reinforcement. A recent placebo- 
controlled study, involving 167 elderly long-term care residents with dementia in 12 facilities in 
Maryland, USA, looked at whether individualized behavioural intervention programs would 
reduce agitated and aggressive behaviours (Cohen-Mansfield, Libin & Marx, 2007). Six of the 
facilities were used as the intervention facilities, while the other 6 conducted treatment as usual. 
Interventions were designed to match the needs of individual residents in areas such as cognitive, 
physical and sensory abilities, as well as their lifelong habits and roles, and occurred for 10 days 
during the 4 hours of greatest agitation for each resident. At the end of the study, it was found 
that there were significant reductions in overall agitation and aggression for the intervention 
group. It was also found that this group had a significant increase in pleasure and interest. 
Increasing physical activity for those with dementia also appears to be a promising 
intervention. Several studies have shown that increased physical activity can improve fitness 
ability, physical function, positive behaviour and cognitive functioning (Heyn, Abreu, & 
Ottenbacher, 2004; Kemoun et al., 2010; Lindenmuth & Moose, 1990). A recent randomized 
control trial looked at the effect of exercise in people with dementia living in long-term care 
facilities (Kemoun et al., 2010). It involved three 1-hour physical activity sessions per week 
(including one session a week of walking, stamina exercises, and dance) and demonstrated that 
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the participants in the intervention group improved their cognitive performance scores and 
walking abilities. In contrast, the participants in the control group had a reduction in their 
baseline cognitive performance scores, and a reduction in both their walking speed and stride 
length. In a large meta-analysis reviewing 30 randomized control trials with older adults with 
cognitive impairment living either at home or in long-term care facilities, improvements were 
found for both cognitive performance (ES = 0.57, 95% Cl = 0.43-1.17), and positive behaviour 
(e.g. reduction in aggression, agitation)(ES = 0.54, 95% Cl = 0.36-0.72) for the exercise groups 
(Heyn, Abreu & Ottenbacher, 2004). 
Psychopharmacological Interventions. Psychopharmacological treatments of BPSD 
are frequently used in individuals with dementia, with medications such as cholinesterase 
inhibitors, mood stabilizers, antidepressants and benzodiazepines, but most commonly with 
antipsychotics (Trifiro, Spina & Gambassi, 2009). Antipsychotics have been shown to be the 
most consistent medications used for treatment of BPSD over the other psychotropic medications 
(Madhusoodanan, Shah, Brenner & Gupta, 2007). 
Antipsychotic medications were first developed in the 1950s for treatment of 
schizophrenia (Banerjee, 2009). Over the next 40 years, many new antipsychotic medications 
were developed and prescribed to those with psychotic illnesses. Older antipsychotic 
medications, including haloperidol and thioridazine, are referred to as conventional or typical 
antipsychotics. These medications bind to the D2 dopaminergic receptors and have been shown 
to cause extrapyramidal symptoms including tardive dyskinesia and parkinsonism (Salzman et 
al., 2008). Most of the newer antipsychotic medications were developed in the early 1990s and 
are termed atypical antipsychotics (Ministry of Health, 2011). These medieations, which include 
drugs such as clozapine, risperidone, olanzapine, loxapine, and quetiapine, have significantly 
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more complex and heterogeneous receptor binding profiles than conventional antipsychotics, and 
have substantially lower rates of extrapyramidal side effects (Trifiro et ah, 2009). 
In Canada, antipsychotic medications are approved for the treatment of psychiatric 
illnesses where there is psychosis, such as schizophrenia and bipolar disorder. No antipsychotic 
medications, except risperidone, are approved for the treatment of BPSD in people with 
dementia. Risperidone has been approved for the, “short-term symptomatic management of 
inappropriate behaviour due to aggression and/or psychosis in patients with severe dementia” 
(Health Canada, 2005, p.l). With the exception of risperidone, the prescription of antipsychotic 
medications to manage BPSD is considered off-label, as the safety and effectiveness of these 
drugs for this purpose has not been proven (Kales et al., 2011). 
In an older study, dispensing trends of antipsychotic medications in Ontario long-term 
care homes were analyzed (Bronskill, Anderson, Sykora, Wodchis, Gill, Shulman & Rochon, 
2004). Participants included 19,780 residents who were 66 years old and older, had not taken an 
antipsychotic medication in the previous year, had no evidence of major psychosis, and had been 
newly admitted to a long-term care facility in Ontario. It was found that antipsychotic 
medications were prescribed to 17% of the residents within 100 days, and 24% of residents 
within the first year since admission. Risk of being prescribed an antipsychotic medication was 
less likely in women (OR = 0.7, 95% Cl = 0.6-0.8), and more likely in residents with dementia 
(OR = 3.5, 95% Cl = 3.2-3.8). In addition, it was found that long-term care residents were 
prescribed an initial does that exceeded recommended thresholds, and that only 14% of those 
newly prescribed an antipsychotic medication had prior contact with a geriatrician or a 
psychiatrist. 
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Between April 2010 and June 2011, 50.3% of seniors in British Columbia on 
PharmaCare Plan B (public drug plan) who resided in long-term care facilities were prescribed 
an antipsychotic medication (Ministry of Health, 2011). The most commonly prescribed 
antipsychotics for these individuals were atypical, including quetiapine, risperidone, loxapine, 
and olanzapine, followed by the conventional antipsychotics haloperidol and methotrimeprazine. 
The rest of Canada had an antipsychotic prescription rate of approximately 37.7% for seniors 
living in long-term care facilities in 2007 (Canadian Institute for Health Information, 2009). 
Trends show that antipsychotic prescription rates for those seniors in long-term care facilities 
have increased in BC over the years from 37% in 2001/02, 47% in 2006/07, to 50.3% in 2011 
(Ministry of Health 2011), and the same trend can be assumed for the rest of Canada. 
Efficacy. There is much debate throughout the medical field regarding the efficacy of 
antipsychotic medications for the management of BPSD, A few studies have found benefits of 
conventional and atypical antipsychotic medications for these symptoms. In a meta-analysis 
looking at the effects of haloperidol in agitated dementia patients, found that there was 
significant improvement in symptoms of aggression, modest improvement in psychotic 
symptoms, but no improvements in agitation (Lonergan, Luxenberg, Colford & Birks, 2002). 
There is very little clinical trial evidence for other conventional antipsychotics with BPSD. In 
another meta-analysis looking at the effects of atypical antipsychotics on aggression, agitation 
and psychosis in dementia patients, it was found that risperidone provided overall benefits for 
behavioural symptoms including aggression, modest benefits for psychosis, and no evidence for 
non-aggressive agitation (Ballard & Howard, 2006). A further meta-analysis looked at the 
effects of risperidone and olanzapine on BPSD in Alzheimer’s disease, and reported a modest 
effect in reducing aggression and psychosis (Ballard & Waite, 2006). 
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The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) was a 42 site, 
double-blind, placebo-controlled drug trial, with 421 outpatient participants with Alzheimer’s 
disease and psychosis, aggression, or agitation (Schneider et ah, 2008). This study compared the 
efficacy of risperidone, olanzapine, and quetiapine with the placebo for a duration of three to 
nine months. Benefits of these medications were limited, with 32% of patients receiving 
olanzapine, 26% of patients receiving quetiapine, 29% of patients receiving risperidone, and 
21 % of patients receiving placebo, exhibiting improved behaviour. Furthermore, this study 
showed that the placebo group had significantly lower health costs than the participants on the 
antipsychotic medications. The authors of this study noted that the adverse events of these 
atypical antipsychotics offset any advantages in the efficacy of these medications. 
A large scale randomized, double-blind, placebo-controlled study, involving 235 long 
term care facility residents with dementia and psychosis, looked at the effectiveness of 
risperidone in the treatment of clinically significant psychosis in Alzheimer’s disease (Mintzer et 
al., 2006). It was found that this medication had no benefit over placebo in reducing psychosis 
rating on the BEHAVE-AD, and that the patients receiving risperidone had more adverse events 
(74% versus 64%), greater and more frequent somnolence (16.2% versus 4.6%), and higher rate 
of mortality (3.8% versus 2.5%), than those taking placebo. Beyond the conflicted research 
findings as to whether there are benefits with using antipsychotic medications for BPSD, it has 
been found that antipsychotic medications do not appear to improve functioning, care needs, or 
quality of life for people with dementia (Sultzer et al., 2008). 
Warnings. In 2002, warnings began to be issued regarding adverse side effects 
(discussed further in next section) of antipsychotic medications when taken by patients with 
dementia. Clinieal trials were starting to show that people with dementia were at a significantly 
Antipsychotic Medications and Dementia 29 
higher risk for life-threatening adverse events when taking antipsychotic medications (Banjeree, 
2009). In October 2002, the manufacturer of risperidone made an unprecedented announcement 
to Canadian healthcare professionals. They shared that in drug-sponsored clinical trials for 
risperidone, it had been found that people with dementia had a higher rate of cerebrovascular 
adverse events (CVAE) compared to those taking placebo (Banjeree, 2009). 
In 2003, the United States Food and Drug Administration (FDA) published its own 
warnings regarding the safety of risperidone for dementia patients, requiring changes to the 
prescribing information (Black & Almeida, 2004). Then, in 2004, the European Medicines 
Agency alerted the public that olanzapine increased the risk of CVAEs and mortality in people 
with dementia. Also in 2004, the United Kingdom Committee of Safety of Medicines 
recommended that physicians avoid prescribing risperidone and olanzapine to elderly people 
with dementia with BPSD due to an increased risk of strokes (Committee on Safety of 
Medicines, 2005). 
In April 2005, the United States FDA issued an alert to health professionals regarding 
increased mortality risk in patients with dementia related psychosis (Federal Drug 
Administration, 2005). This alert was based on the findings of seventeen independent 
randomized clinical trials using the antipsychotic drugs olanzapine, aripiprazole, risperidone, and 
quetiapine. 5106 elderly patients with BPSD took part in the studies as well as additional control 
participants. The drug trials showed that the risk of death was 1.6 to 1.7 times higher for those 
participants taking the antipsychotic medications than the control participants on a placebo over 
an approximate 10 week period. Causes of the deaths were identified as primarily cardiovascular 
(e.g. heart failure) and infectious (e.g. pneumonia). The FDA found similar results of increased 
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risk for death with conventional antipsychotics, but refrained from issuing an alert because data 
was only based on one randomized control trial with haloperidol (Trifirb et al., 2009). 
Health Canada also issued a warning in June 2005 regarding the safety of using atypical 
antipsychotic medications for the treatment of behavioural and psychological symptoms in 
elderly patients with dementia (Health Canada, 2005). This warning was based on the results of 
thirteen placebo-controlled studies using the atypical antipsychotics risperidone, quetiapine, and 
olanzapine for the treatment of behavioural and psychological symptoms in elderly patients (n = 
3965) with dementia. It was found that the risk of death was 1.6 times greater in the participants 
receiving the antipsychotics. Cause of death was typically due to cardiovascular events and 
infections, or consistent with what was found in the American studies. Due to these findings, 
Health Canada requested the manufacturers of atypical antipsychotic medications include a 
warning on their Product Monograph describing the risks of these medications and noting that 
they are not approved for treatment of behavioural and psychological symptoms in elderly 
patients with dementia, with the exception of risperidone. In 2008, the FDA followed suit and 
required their antipsychotic medication manufacturers to provide warnings of the increased risk 
of death in elderly patients with BPSD with off-label use (Trifiro et al., 2009). 
These warnings fueled the debate over whether antipsychotic medications should be used 
to treat behavioural and psychological symptoms in elderly patients with dementia. Mowat, 
Fowlie and MacEwan (2004) sent a letter to the editor of the British Medical Journal stating that 
they believe atypical antipsychotics are highly effective and that “the blanket injunction issued 
by the Committee on Safety of Medicines is oversimplified and may prove detrimental to patient 
care” (p. 1262). A large number of other studies have been conducted since the warnings were 
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issued, confirming an increased risk of death for elderly dementia patients taking antipsychotic 
medications, as well as finding numerous other health concerns related to antipsychotics. 
Side Effects. 
All-cause mortality. All-cause mortality refers to the overall death rate for a population 
regardless of specific cause (e.g. heart attacks, strokes). At this point, there is significant 
evidence that antipsychotic medications increase the risk of mortality. Large scale meta-analyses 
have consistently shown increased risk of death when people with dementia are treated with 
atypical antipsychotic medications. A meta-analysis of seventeen independent randomized 
controlled trials with 5106 elderly demented patients with BPSD, including the atypical 
antipsychotic medications olanzapine, aripiprazole, risperidone, and quetiapine, found that 
overall mortality was 4.5% for patients treated with these antipsychotic medications compared to 
2.6% for patients on placebo (Federal Drug Administration, 2005). In another meta-analysis of 
thirteen controlled studies with 3965 participants with BPSD, it was found that the risk of death 
was 1.6 times higher for those taking the atypical antipsychotics olanzapine, risperidone, and 
quetiapine, than those taking placebo (Health Canada, 2005). 
These meta-analyses were said to provide conclusive evidence that atypical antipsychotic 
medications increased risk for all-cause mortality in older adults with dementia, so the focus of 
drug trials was redirected towards the risks associated with conventional antipsychotics (Trifiro 
et al., 2009). In a study with 27,259 match pairs of dementia patients, it was found that there is a 
significant increase in the risk for death for those taking antipsychotic medications at 30 days, 
when compared to those not taking an antipsychotic, which persisted to the end of the study at 
180 days (Gill et al., 2007). The risk of death in this study was greater for those prescribed 
conventional antipsychotic medications than those who were taking atypical antipsychotics. 
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A large scale study, conducted in the United States, looked at the risk of death in elderly 
people taking either a conventional or atypical antipsychotic medication and found that 
conventional antipsychotic medications were at least as likely to increase risk of death than 
atypical medications (Wang et al., 2005). In the conclusion of this study, it was warned that 
conventional medications should not replace the use of atypical medications that were involved 
in recent FDA warnings. A study looking at elderly patients in British Columbia who were 
taking either a conventional or atypical antipsychotic medication, it was found that within the 
first 180 days of starting the medication, 14.1% of those in the conventional medication group 
died, while only 9.6% of those taking an atypical antipsychotic passed away (Schneeweiss, 
Setoguchi, Brookhart, Dormuth & Wang, 2007). In an Italian study, it was found that elderly 
people with dementia who took an atypical antipsychotic medication were at a two-fold risk for 
death, whereas those taking a conventional antipsychotic were at a four-fold risk for death, 
compared to controls (Musicco et al., 2011). 
In a study looking at the long-term survival rates for those with Alzheimer’s disease 
taking either an atypical or a conventional antipsychotic medication, or a placebo, showed 
similar results (Ballard et al., 2009). Participants were randomly assigned to take either 
thioridazine, chlorpromazine, haloperidol, trifluoperazine, risperidone, or placebo. It was found 
that survival rate for the antipsychotic group was 46% compared to 71% in the placebo group at 
24 months, 30% versus 59% at 36 months, and 26% versus 53% at 42 months. 
A study was recently conducted, looking at the risk of short-term mortality in 508 
Ontario long-term care facilities based on dispensing rates of antipsychotic medications 
(Bronskill et al., 2009). The study included 60,105 individuals 66 years of age and older who 
were newly admitted to a long-term care facility between the years of 2000 and 2004. Facilities 
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were assigned to one of five groups (quintiles), with Q1 having the lowest antipsychotic 
dispensing rate and Q5 having the highest. It was found that the average dispensing rate of 
antipsychotic medications ranged from 11.6% of residents in Ql, and increased to an average of 
30.0% in Q5. When looking at individuals who did not have a recent hospitalization, it was 
found that all-cause mortality rates at 30 days was 2.5% for Ql and 3.3% for Q5. At 120 days, 
this rate increased to 9.3% for Ql and 11.7% for Q5. This study showed that despite similar 
admission characteristics, those long-term care residents who were simply admitted to a facility 
that dispensed greater quantities of antipsychotic medications (e.g. Q5 versus Ql), faced an 
increased risk of death. 
Cardiovascular events. In 2005, Health Canada issued a warning about the increased risk 
of death and adverse events from the use of atypical antipsychotic medications in the elderly 
patients with dementia (Health Canada, 2005). This warning stemmed from the review of 
thirteen placebo-controlled studies using risperidone, quetiapine, and olanzapine in elderly 
patients with BPSD, that showed a mean 1.6 fold increase in death rate this population taking 
these medications. The majority of deaths in these studies were due to heart related events 
including heart failure and sudden-death. The United States also issued a warning in 2005 based 
on seventeen studies focusing on older adults with dementia (Federal Drug Administration, 
2005). These studies found that cardiovascular events, including sudden cardiac death and 
myocardial infarction, were the most common reason for death in older adults with dementia 
taking either an atypical or conventional antipsychotic. 
In a recent study looking at community-dwelling older adults who take antipsychotic 
medications, it was found that the unadjusted risk of death associated with taking antipsychotic 
medications was approximately three times that of people who did not use these medications. 
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and double that of non-users after adjusting for demographics, diagnostic differences, an 
antidepressant use (Gisev, Hartikainen, Chen, Korhonen & Bell, 2012). In this study, the highest 
adjusted risk of death was found in those people using antipsychotic medications who had a 
baseline diagnosis of respiratory disease. Another study that looked at the risk for serious 
cardiac events in older adults taking antipsychotic medications found that after controlling for 
duration of therapy and other exposures probable to induce cardiovascular risk, participants 
taking conventional antipsychotics were 20% more likely to have a serious cardiac event (Mehta, 
Chen, Johnson & Aparasu, 2011). 
Cardiac arrhythmias have been associated with antipsychotic medications in older adults. 
Conventional antipsychotics have been shown to contribute to serious cardiac events by 
increasing the risk of prolongation of cardiac repolarization and the QTc interval, causing 
orthostasis, and tachyarrhythias (Drici & Priori, 2007). Atypical antipsychotics may trigger 
sinus tachycardia, atrial and ventricle extrasystoles, as well as rate-corrected QTc inverval 
prolongation, T wave inversion, ST segment depression, and atrioventricular blocks (Haddad & 
Anderson, 2002). 
In studies related to venous thrombosis (a blood clot in a vein), pulmonary embolisms (a 
blockage in the main artery of the lung or one of its branches), and venous thromboembolism 
(VTE) (a venous thrombosis that causes a pulmonary embolism), an association has been made 
between occurrences of these conditions and older people taking antipsychotic medications. One 
study looked at the risk of hospitalization for VTE among elderly patients living in long-term 
care facilities who were taking either an atypical or conventional antipsychotic (Liperoti, 
Pendone, Lapane, Mor, Bemabei & Gambassi, 2005). After adjusting for potential confounding 
factors, it was found that users of atypical antipsychotics including risperidone, olanzapine. 
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clozapine and quetiapine had an increased risk of hospitalization for VTE, while those taking a 
conventional antipsychotic had no increased risk compared to controls. A case-control study 
showed that the risk of VTE was 3.5 times greater for those using antipsychotic medications than 
those who are not, which occurred at the rate of 4:1 for atypical and conventional antipsychotics 
respectively, in people 68 years of age (Lacut et al., 2007). 
Cerebrovascular adverse events. Cerebrovascular adverse events (CVAE), such as 
strokes and transient ischaemic attacks (TIA), are caused by disruption of blood supply to the 
brain, typically caused by a cerebral infaretion or hemorrhage. It has been found that dementia 
patients taking risperidone or olanzapine had a risk three times greater for strokes and TIAs than 
those taking placebo (De Deyn, Katz, Brodaty, Lyons, Greenspan & Bums, 2005; Wooltorton, 
2004). A post hoc analysis of pooled results from eleven randomized controlled trials of 
risperidone and olanzapine in elderly dementia patients found statistically significant differences 
in the occurrence of CVAEs, with 2.2% of drug treated patients experiencing these events 
compared to 0.8% of placebo treated patients (Herrmann & Lanctot, 2005). 
In a meta-analysis ineluding 15 eontrolled trials using atypical antipsychotics 
(aripiprazole, olanzapine, quetiapine, and risperidone) with placebos, it was found that there is an 
increased odds ratio by meta-analysis for CVAEs in those on antipsychotics of 1.9% versus 0.9% 
pooled (Schneider, Dagerman & Insel, 2006). When risperidone was specifically looked at in 
this meta-analysis, the risk was even greater at 3.1% versus 1.0% pooled. In ease control studies, 
it has been found that patients with dementia taking antipsychotic medications had a 1.3 to 2 
times greater risk of a CVAE, than those not taking these medications (Sacchetti, Turrina & 
Valsecchi, 2010). Sacchetti et al. (2010), determined that the highest risk of stroke is within the 
first weeks of treatment with antipsychotic medications, and risk factors for strokes in this 
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population include older age, cognitive impairment, and pre-existing vascular illness. In a 
comprehensive literature review, it was found that risk for CVAEs in dementia patients being 
treated with antipsychotic medications for BPSD was similar for conventional and atypical 
antipsychotics, and increased due to factors such as male gender, higher severity of dementia, 
greater functional impairment, and comorbid conditions such as atrial fibrillation (Mittal, Kurup, 
Williamson, Muralee & Tampi, 2011). 
Cognitive decline. Cognitive decline has been shown to be accelerated in older people 
with dementia taking antipsychotic medications. People with dementia taking olanzapine or 
risperidone have been documented in one study to have significantly greater rates of cognitive 
decline than patients receiving placebo, when they took the medication for at least two weeks 
prior to assessment (Vigen et al., 2011). Another study, looking at the effects of quetiapine on 
cognitive impairment in older adults with Alzheimer’s disease, found there was signifieant 
decline compared to placebo (Ballard et al., 2005). Participant’s cognitive impairment level was 
measured with the Severe Impairment Battery, that has a maximum score of 152. At the six- 
week follow-up, the quetiapine group scored an average of 14.6 points less (worse) than the 
placebo group and 15.4 points less at 26 weeks. 
In a two year prospective longitudinal study, it was reported that cognitive decline was 
doubled for older people with dementia taking a conventional antipsychotic medication, 
compared to those who did not (McShane, Keene, Gedling, Fairburn, Jacoby & Hope, 1997). It 
was also found in this study that the rate of cognitive decline was more rapid when the 
antipsychotic medication was initiated, rather than towards the end of study, and that cortical 
Lewy body pathology did not explain the association between antipsychotic use and faster 
cognitive decline at autopsy. Atypical antipsychotics were also confirmed to significantly 
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increase the rate of cognitive decline in a meta-analysis (Schneider et al., 2006). This analysis 
looked at Mini-Mental State Exam scores over 12 weeks in placebo-controlled trials, and showed 
that atypical antipsychotic medications caused more rapid cognitive decline in dementia patients. 
Extrapyramidal Extrapyramidal symptoms (EPS) are movement disorders such as 
Parkinsonism, akathisia, dystonia, and tardive dyskinesia, caused by the effects of antipsychotic 
medications on dopamine receptors. It has been well documented that conventional 
antipsychotics are highly associated with developing EPS, and less so with atypical 
antipsychotics (Czamecki, Kumar & Josephs, 2008). The inequality in EPS prevalence between 
conventional and atypical antipsychotics is believed to be due to the differences in their 
pharmaeological mechanisms on dopamine receptors (Weiden, 2007). 
Acute EPS develops within hours to weeks of the initiation of antipsychotic medications 
and can include Parkinsonism, akathisia, and acute dystonia (Czamecki et al., 2008). 
Parkinsonism refers to motor issues that mirror those of Parkinson’s disease, commonly caused 
by antipsychotic medications. Motor issues may include a decrease in facial expressions, 
difficulty starting and controlling movement, loss or weakness of movement (paralysis), tremor, 
and stiffness of the body or limbs (American Psychological Association, 2000). Akathisia is a 
syndrome of persistent restlessness which may be perceived as extreme anxiety. People with 
akathisia have compulsive movements, such as fidgeting, marching in one spot, pacing, or 
swinging legs when sitting in a chair, in order to help relieve their restlessness (Chang & 
Friedman, 2009). Acute dystonia involves sustained abnormal body postures or muscle spasms 
(American Psychological Association, 2000). Abnormal positioning commonly includes the 
head and neck but can also target the body and limbs. Spasms can affect the jaw muscles, as 
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well as effect ability to swallow, speak or breath. At times, acute dystonia can affect the eyes 
causing an oculogyric crisis, causing the eyes to deviate up, down, or sideways. 
Conventional and atypical antipsychotics have been compared to see what group of 
medications cause the most risk for EPS. The conventional antipsychotic haloperidol has been 
consistently shown to induce the highest risk for EPS (Geddes, Freemantle, Harrison & 
Bebbington, 2000; Bagnall et al., 2003; Crespo-Facorro, Perez-Inglesias, Ramirez-Bonilla, 
Martinez-Garcia, Llorca, Vazquez-Barquero, 2006). Risperidone is believed to cause the 
greatest risk of Parkinsonism than all other atypical antipsychotics (Yang, Kao Yang, Chong, 
Yang, Chang & Lai, 2007). One study found that risperidone caused Parkinsonism in 42% of 
participants, with haloperidol only causing parkinsonism in 29% (Knable, Heinz, Raedler & 
Weinberger, 1997). Another study found no differences in the incidence of developing 
parkinsonism, acute dystonia, or akathisia when treated with risperidone or haloperidol 
(Rosebush & Mazurek, 1999). When looking at the risk for EPS between atypical 
antipsychotics, it has been found that risperidone was associated with the highest risk, and 
clozapine and quetiapine had the lowest risk (Weiden, 2007). 
Tardive dyskinesia has a late onset and may appear months or years after initial treatment 
with antipsychotic medications. Tardive dyskinesia involves involuntary movements of the 
tongue, jaw, body or limbs due specifically to the use of antipsychotic medications (American 
Psychological Association, 2000). The involuntary movements may include choreiform (rapid, 
jerky, non-repetitive), athetoid (slow, sinuous, continual), or rhythmic (stereotypies). 
Conventional antipsychotics are known to cause the highest risk of tardive dyskinesia, with an 
incidence of 5% per year in a study non-specific to older people with dementia, compared to 
atypical antipsychotics that have an incidence of 1% per year (Tarsy & Baldessarini, 2006). 
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Elderly people are seen as the highest risk group for tardive dyskinesia (Trifiro et ah, 2009), and 
the incidence of EPS has been shown to be higher in elderly dementia patients at a conservative 
rate of 2.6% per year (Jeste, Okamoto, Napolitano, Kane & Martinex, 2000). 
Pneumonia. In studies regarding the development of pneumonia in elderly people taking 
antipsychotics the results are fairly consistent. While some of these studies do not focus 
specifically on dementia, they regularly show that there is an increased risk for pneumonia for 
older adults taking antipsychotic medications. A study containing 22,944 elderly participants 
who had received a prescription for antipsychotic drugs (Knol, van Marum, Jansen, Souverein, 
Schobben & Egberts, 2008). It was found that after controlling for confounding factors, the 
current use of antipsychotics in older adults was associated with a 60% greater risk of pneumonia 
than controls using no antipsychotics. In this study, risk for developing pneumonia was equal for 
both conventional and atypical antipsychotics. 
A study that looked at the risk for developing pneumonia after the initiation of atypical 
antipsychotics in older adults found that there was a 70% increased risk compared to controls 
(Pratt, Roughead, Ramsay, Salter & Ryan, 2011). In another study, using 258 older adults 
hospitalized with pneumonia who were taking antipsychotic medications, it was found that 25% 
died within 30 days, which was significantly greater than controls (Trifiro et al., 2010). It was 
also found that there was a dose dependent increase in the risk for pneumonia when taking 
antipsychotic medications in this population, but only atypical antipsychotics were associated 
with an increased risk for fatal pneumonia. Risk for the development of pneumonia for both 
conventional and atypical antipsychotics in older adults has been found to be the highest in the 
first week of taking the medication, and then returning to base-line levels after 90 days of 
treatment (Knol et al., 2008). 
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Falls and fractures. Some research has found that the risk of falls and fractures is 
increased for dementia patients taking antipsychotic medications. A study by Kolanowski, Pick, 
Waller and Ahern (2006), showed that the risk of falls and hip fractures was increased for those 
people taking either a conventional or atypical antipsychotic. These results mirror what was 
found in a study looking at risk of hospitalization for a femur fracture (Liperoti et al., 2007). 
Risk for femur fracture was increased for those on atypical antipsychotics (OR = 1.37, 95% Cl = 
1.11 to 1.69) and conventional antipsychotics (OR - 1.35, 95% Cl = 1.06 to 1.71) compared to 
non-users. Haloperidol posed the highest risk for femur fracture (OR = 1.53, 95% Cl = 1.18 to 
2.26) followed by risperidone (OR = 1.42, 95% Cl = 1.12 to 1.80) and olanzapine (OR = 1.34, 
95% Cl = 0.87 to 2.07). In an observational study in Australia with residents in long-term care, 
it was found that the participants taking either atypical or conventional antipsychotics had a 35% 
to 70% increased risk for falls (Hien et al., 2005). Conversely, other studies looking at the rate 
of falls in people with dementia did not show increased risk for those taking risperidone when 
compared with placebo (Katz, Mintzer, Brodaty, De Deyn & Greenspan 2005). 
Summary 
Dementia is a neurodegenerative disease that currently effects 480,600 people in Canada, 
with estimates that this number will grow to 1,125,200 within the next 25 years (Alzheimer 
Society of Canada, 2010). Beyond the cognitive symptoms, dementia can cause severe 
behavioural and psychological symptoms, including disruptive behaviours such as aggression 
and agitation. These symptoms have a significant negative effect on the individual suffering 
from dementia, as well as their family, caregivers, and others around them (CIHI, 2010). When 
BPSD is severe, most families have no choice other than to admit their loved one to a long-term 
care facility (Lyketsos et al., 2000). 
Antipsychotic Medications and Dementia 41 
Strategies to manage BPSD include psychosocial interventions as well as 
psychopharmacology. The psychosocial interventions that have the most support within the 
literature involve staff training within the long-term care facilities. This type of training teaches 
the staff ways to improve the quality of life of those with dementia, by understanding the 
potential causes of disruptive behaviour, how to focus on the individual’s strengths, and how to 
compensate for their existing functional deficits (Vemooij-Dassen et ah, 2010). The GPA, is a 
well-regarded intervention that is being taught and implemented in long-term care facilities 
throughout Ontario and other parts of Canada (Pettit, 2012). This approach also trains staff to 
understand that the aggressive and agitated behaviours displayed by those with dementia 
typically result from unmet needs, and may be the only way the individual with dementia is able 
to communicate issues, protect themselves, and take control over their increasingly unfamiliar 
and frightening world (Speziale et ah, 2009). 
Other psychosocial interventions are created directly for those suffering from dementia. 
Cognitive stimulation therapy tries to stimulate brain function and alertness, and has been shown 
to help reduce depression and potentially mildly reduce behavioural symptoms (Livingston et ah, 
2005). Behavioural management techniques focusing on individual patient’s needs, such as 
problem solving techniques, progressive muscle relaxation, reminiscence, and positive 
reinforcement have shown positive effects on reducing aggression and agitation, while increasing 
pleasure and interest (Cohen-Mansfield, Libin & Marx, 2007). Increased physical activity has 
also been shown to have a promising effect on reducing behavioural issues including aggression, 
as well as increasing physical fitness, physical function, cognitive functioning, and mood 
(Kemoun et ah, 2010). While some positive results have been shown in these psychosocial 
interventions, the research in this area is sparse and not well developed. 
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Psychopharmacological interventions are frequently used to help manage BPSD. The 
most common form of medication prescribed for these symptoms, especially for aggression and 
agitation and antipsychotics (Trifiro et ah, 2009). These medications were first developed in the 
1950s, conventional antipsychotics, to treat psychotic illnesses, such as schizophrenia. In the 
early 1990s, the receptor binding profiles of conventional antipsychotics were made more 
complex and heterogeneous, creating a new class of antipsychotics, termed atypical 
antipsychotics (Trifiro et al., 2009). No conventional or atypical antipsychotics, with the 
exception of the atypical antipsychotic risperidone, have been approved to treat BPSD in 
Canada. Risperidone is only approved to be prescribed short-term to manage aggression and/or 
psychosis in those with severe dementia (Health Canada, 2005). While antipsychotic 
medications are not approved to manage BPSD, up to 50% of seniors residing in long-term care 
facilities in Canada, most would be diagnosed with dementia, are taking at least one of these 
medications (Ministry of Health, 2011). 
While antipsychotic medications are commonly prescribed to people with dementia, there 
is controversy as to whether they are effective in treating BPSD. The research in this area is rife 
with conflicting results showing that these medications are and are not beneficial. When taken 
together, it appears that there may be some limited effectiveness of both conventional and 
atypical antipsychotics in reducing BPSD, including aggression and agitation. 
Warnings over the safety of antipsychotic medications in older people with dementia 
started to emerge in 2002, when the manufacturer of risperidone announced to Canadian 
healthcare professionals that there is a significantly increased risk of CVAE in people with 
dementia taking this medication. At least seven subsequent warnings regarding the safety of all 
antipsychotic medications, conventional and atypical, were issued in the United States, Europe 
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and Canada over the next six years, stating that there is an increase in cardiovascular events, 
CVAEs and death in dementia patients taking these medications. 
Over the past 10 years, a plethora of research has warned about significant side effects 
with the use of this medication in dementia patients. It has been shown that people with 
dementia taking an atypical antipsychotic are at a twofold risk of death, and those taking a 
conventional antipsychotic are at a fourfold risk of death, than people with dementia not taking 
these medications (Musicco et ak, 2011). In a large meta-analysis of 17 studies focusing on 
older adults with dementia, it was found that cardiovascular events, such as sudden cardiac death 
and myocardial infarction, were the most common reason for death in this population taking 
either an atypical or conventional antipsychotic medication (Federal Drug Administration, 2005). 
The risk for CVAEs, including strokes and TIAs, are significantly increased for people with 
dementia taking these medications, with one study showing that people with dementia taking 
either risperidone or olanzapine having a risk three times greater for strokes and TIAs than 
controls (De Deyn et ak, 2005). 
Cognitive decline has been shown to be accelerated in people with dementia taking these 
medications (Vigen et ak, 2011), and the development of EPS well documented, especially with 
conventional medications (Czamecki et ak, 2008). The risk of developing pneumonia is also 
increased for elderly people taking antipsychotic medications, regardless of dementia diagnosis. 
One study found that those individuals taking an atypical or conventional antipsychotic 
medication were at a 60% greater risk for developing pneumonia (Knol et ak, 2008). Lastly, 
some studies have shown that the risk for falls and fractures in people with dementia taking an 
antipsychotic medication are significantly increased compared to controls (Hien et ak, 2005; 
Kolanowski et ak, 2006; Liperoti et ak, 2007). 
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While it is evident that there is promise for psychosocial interventions in the treatment of 
BPSD, especially for aggressive and agitated behaviours, antipsychotic medications appear to be 
the intervention most commonly used. Even with significant government warnings regarding the 
use of antipsychotic medications in older adults with dementia, and research showing undeniable 
evidence of severe, and sometimes deadly, side effects, these medications are being widely 
prescribed in Canada to individuals in this population, especially in long-term care homes. At 
this point, it is important to gain a clear picture of the current prescribing trends of antipsychotic 
medications in older adults with dementia in Canada. It will also be beneficial to determine the 
side effects these medications are having on individuals with dementia in our long-term care 
homes, and whether there are any visible benefits with their use. 
Current Study 
Antipsychotic medications continue to be prescribed to older adults with BPSD, even 
after significant safety warnings were issued from Health Canada in 2004, with very limited 
evidence for any meaningful benefit within this population. As previously shown, side effects 
from these medications in older adults with dementia are numerous and potentially severe, 
including increased risk of death. 
The current study provides the most comprehensive look at the current use, and effects, 
of antipsychotic medications in older adults in continuing care facilities in Canada. Although 
earlier studies (except those with interventional designs) were mainly cross-sectional, the present 
research will focus on longitudinal trends. The main dataset in the study is the Resident 
Assessment Instrument - Minimum Data Set 2.0 (MDS). A brief history of its use in continuing 
care follows. In 1996, complex continuing care facilities (CCC) in Ontario started to collect 
data using MDS 2.0. The MDS tool gathers information that includes behaviours (e.g.. 
Antipsychotic Medications and Dementia 45 
aggressive behaviour), physical competence (e.g., activities of daily living), cognitive status 
(e.g., overall performance, delirium), and indicators of overall health status (e.g., frailty) and 
specific diagnoses. In 2005, long-term care (LTC) facilities in Ontario also started to collect 
MDS 2.0 data, at which time the Ontario Ministry of Health and Long-Term Care mandated its 
use in all LTC facilities use by June 2010. This process was gradual, with 20 facilities collecting 
data in 2005, and 217 facilities (39%) by the spring of 2009. The remaining 411 facilities in 
Ontario were collecting data by the summer of 2010. The data used in this study was the full 
year census level data for 2010/2011 and 2011/2012 when all facilities in Ontario were using the 
MDS 2.0. 
The MDS 2.0 data are available from the Canadian Institute for Health Information 
(CIHI), which also provided linkages with two other datasets. First, all Canadian hospitals 
(except those in Quebec) submit their separations records directly to CIHI for inclusion in the 
Discharge Abstract Database (DAD). The database contains demographic, administrative and 
clinical data for hospital discharges (inpatient acute, chronic, rehabilitation) and day surgeries. 
Second, the National Ambulatory Care Reporting System (NACRS) contains data for hospital- 
based and community-based emergency and ambulatory care (for example, day surgery and 
outpatient clinics). The main purposes of these additional datasets are to provide information on 
mortality in other than the primary CCC or LTC residence. 
Issues within study 
There were problematic issues related to medications that were known prior to running this 
study. The first was regarding the type of antipsychotic administered to participants during the 
study period. This information was not recorded on the RAI. Consequently, the analyses did not 
take into account the differences regarding the elass of antipsychotic medication participants 
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were taking (e.g. atypical versus typical), nor did they look at the differences between specific 
medications (e.g. risperidone versus quetiapine versus olanzapine). Second, the database 
contains no information on dosage, meaning that dosage effects could not be analyzed. 
Therefore, the use of antipsychotic medications was only analyzed with respect to indexes based 
on frequency of use per week within the specified period of time. In addition, the frequency of 
administration, was not recorded within the database. 
Lastly, antipsychotic medications are also prescribed to older adults for reasons other than to 
help manage the behavioural symptoms of dementia. Older adults with schizophrenia (Jeste & 
Maglione, 2013), bipolar disorder (Dolder & Mckinsey, 2011), and cancer (Fisch & Kim, 2004) 
are regularly prescribed antipsychotic medications to help control symptoms related to the 
respective illnesses, which may confound the results in the current study if not taken into 
account. Rather than excluding participants with a diagnosis of any of these illnesses, as done in 
a previous study (Huybrechts, Gerhard, Crystal, Olfson, Avom, Levin, Lucas & Schneeweiss, 
2012), participants with these illnesses were controlled for within the multilevel modeling 
analyses in this study. 
Purpose of Research 
The purpose of this research study was threefold. First, this study aimed to explore the 
nature of demographics within CCC and LTC facilities, regarding issues such as health and 
behaviour. Second, detailed information on the use of antipsychotic medications in these 
facilities was sought, with speeific reference to those partieipants using this class of medication 
who also a diagnosis of dementia or were exhibiting aggressive behaviour. It was hypothesized 
that based on preceding evidence, approximately 40% to 50% of residents in CCC or LTC 
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facilities would be receiving antipsychotic medications at any given time (CIHI, 2009; Ministry 
of Health, 2011). 
It was also hypothesized that those participants receiving antipsychotic medications 
would be more likely to have a diagnosis of dementia and have a higher level of aggressive 
behaviours than those who are not. With that being said, it is estimated that those with severe 
cognitive impairment would be prescribed antipsychotic medications less frequently than those 
with moderate or no cognitive impairment due to the reduction of mental and physical abilities, 
including aggressive behaviour, commonly witnessed in these patients. 
Lastly, this study aimed to identify the effects of antipsychotic medication use on 
mortality in those residing in CCC and LTC facilities. It is hypothesized that those participants 
receiving antipsychotic medications will have a higher rate of mortality than those who are not 
taking them, consistent with past research (Federal Drug Administration, 2005; Health Canada, 
2005; Musieco et al., 2011). Banarjee (2009) adjusted a refinement of this hypothesis, which 
was tested in the present research, that there is a higher risk of mortality associated with longer 
durations of antipsychotic medication use. 
Method 
Participants 
MDS 2.0 assessment data for all CCC and LTC facilities in Ontario were obtained from 
CIHI for the financial years 2010-2011 and 2011-2012. The data was census level for both CCC 
and LTC, with data collected quarterly, eontaining 102,658 participants in total. The eomposite 
data set also included linkages to mortality and other relevant entries in the DAD and NACRS 
datasets. These datasets were merged into one to include all participants age 65 and older that 
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had census level data for the time period analyzed. The primary analyses were on residents 
entering a facility during the time period encompassed by the study. 
MDS 2.0 Indexes 
The MDS is a system of standardized instruments that assess eomplex populations across 
various health and social service sectors, including CCC and LTC facilities (Hirdes, Mitchell, 
Maxwell & White, 2011). These instruments are widely used around the world including North 
America, Europe, Asia, the Middle East, South America, New Zealand, and Australia. The MDS 
has been continuously evaluated and refined through researeh to ensure and maintain high levels 
of reliability (Hirdes et ah, 2008; Poss et al, 2008; Sgadari et ah, 1997) and validity (Carpenter, 
2006; Fries, Simon, Morris, Flodstrom & Bookstein, 2001; Morris, Jones, Fries & Hirdes, 2004) 
aeross care settings. 
The current study included MDS 2.0 outcome measures and morbidity related variables, 
in addition to mortality data. Status and outcome scales are embedded within the MDS and can 
be used to evaluate a resident’s current clinical status, and change in clinical status where 
longitudinal data is eollected on a particular resident. Illness related variables, sueh as dementia, 
cognitive decline, aggression, and depression, were used to evaluate the effects that 
antipsychotics had on these symptoms. The variable related to the change in MDS scale seores 
indicated the difference in each score from the first assessment to last assessment, for the five 
MDS seales. Variables were seleeted for relevanee as well as for known reliability and validity 
against gold standard measures. Additionally, some variables that are caused by antipsychotic 
medications, like falls, were not included in the analyses because they are already accounted for 
within the variables related to antipsychotic medications. 
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Outcome Measures 
Activities of Daily Living (ADL) Scale. The ADL Scales (Short Form, Long Form, and 
Self-Performance Hierarchy) looked at the resident’s ability to perform normal day to day 
activities, for example dressing, personal hygiene, toilet use, locomotion, transfer, bed mobility, 
and eating. The ADL scales assessed these activities according to the level of impairment faced 
by the resident, with ADLs that are lost early in disability, such as dressing, are given lower 
scores than those ADLs that are lost later in disability, such as eating. All the ADL scales have 
been shown to have good reliability and validity with positive predictive values between .6 and 
.7 and the long form achieving an alpha inter-consistency level exceeding .85 (Mor, Intrator, 
Unruh & Cai, 2011). The present study will use the hierarchy measure. 
Aggressive Behaviour Scale (ABS). The ABS is a summary scale of four MDS items, 
including verbal abusive (e.g. screaming at others), physical abusive (e.g. hitting others), socially 
inappropriate or disruptive behaviour (e.g. throwing food), and resisting care (e.g. pushing 
caregiver during ADL assistance) (Perlman, & Hirdes, 2008). Aggressive behaviour is coded 
over seven days on ABS items, as not exhibited (0), behaviour occurred 1 to 3 days in the past 7 
days (1), behaviour occurred 4 to 6 days in the past 7 days but less than daily (2), or behaviour 
occurred daily (3). Scores range from 0 to 12, with more frequent measured behaviours resulting 
in a higher score. Reliability for the ABS is good, with alphas of 0.79 and 0.93, and strong 
concurrent validity (correlation coefficient = 0.72, P<.001) when compared to the aggression 
subscale of the well validated Cohen-Mansfield Agitation Inventory (CMAI)(Perlman & Hirdes, 
2008). Similar results were found in a more recent study comparing the ABS and CMAI (p = 
0.54, P = .004), however, in this study, the ABS did not correlate with the Neuropsychiatric 
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Inventory-Nursing Home Edition (NPI) Agitation/aggression subscale (p = 0.10, P = .628) 
(Smart, Herrmann, & Lanctot, 2011). 
Changes in Health, End-Stage Disease and Symptoms and Signs Scale (CHESS). The 
CHESS scale predicts mortality and clinical instability, and identifies individuals at risk of 
serious health decline. The CHESS scale is a six point scale with 0 = not at all unstable to 5 = 
highly unstable, with higher scores being predictive of worse outcomes such as mortality, 
hospitalization, pain, caregiver stress, and poor self-rated health (Hirdes, Frijters & Teare, 2003). 
Symptoms measured on this scale included shortness of breath, edema, weight loss, leaving food 
uneaten, vomiting, dehydration, end-stage disease, decline in cognition, and decline in ADLs. 
The CHESS scale is a strong predictor of mortality (P <.001) independent of age, gender, ADL 
impairment, and cognition, in addition to being strongly associated with physician involvement, 
complex medical procedures, and pain (P <.001 for each) (Hirdes, Frijters & Teare, 2003). 
These results have been confirmed by a large scale study looking at the predictability of 
mortality in nursing home residents using the CHESS scale (Lee, Chau, Hui, Chan, & Woo, 
2009). It was found that shorter survival was independently associated with more frail CHESS 
scale scores (HR = 1.150 per 1-unit increment, 95% Cl 1.042-1.268, P = 0.005) in individuals 
after admission to a nursing home care facility. 
Cognitive Performance Scale (CPS). The CPS is used to determine the cognitive status 
of residents in CCC and LTC facilities. It is based on five items: comatose, short-term memory, 
cognitive skills for daily decision making, expressive communication, and eating self 
performance. Scores range from 0 to 6, with 0 being intact cognitive functioning and 6 being 
very severe impairment. The CPS has been validated against the Mini Mental State Exam 
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(MMSE) and the Test for Severe Impairment (TSI), Eta2 = 0.75 for the MMSE and 0.80 for 
MMSE and TSI combined (Morris et al., 1994). 
The diagnostic accuracy of the CPS has been shown to be similar to the MMSE in 
another study (Paquay, De Lepeleire, Schoenmakers, Ylieff, Fontaine, & Buntinx, 2007). The 
diagnostic values of a CPS score of two or more for the detection of cognitive impairment in this 
study were: sensitivity = 0.81, specificity = 0.80, PPV = 0.92, and NPV = 0.57. The diagnostic 
values of a MMSE score of less than or equal 23 in the same study were: sensitivity = 0.97, 
specificity = 0.59, PPV = 0.88, and NPV = 0.85. For CPS, the area under the receiver operating 
characteristic (ROC) curve was 0.87 (95% Cl, 0.81-0.91), and not significantly different (p = 
0.63) from the MMSE score, 0.88 (0.83-0.93. A recent study looking at the validity between the 
CPS and MMSE found similar results (p = -0.57, P = .003, sensitivity = 0.69, specificity = 0.70, 
PPV = 0.79, NPV = 0.58)(Smart, Herrmann, & Lanctot, 2011). Inter-rater reliability is also good 
with the Spearman-Brown inter-rater reliability coefficients for the CPS items averaging .85 
(Morris et al., 1994). 
Depression Rating Scale (DRS). The DRS is used to measure symptoms of depression 
including: negative statements; persistent anger; expression of unrealistic fears; repetitive health 
complaints; repetitive anxious complaints; sad, pained, worried expression; and tearfulness. The 
scale is based on frequency of symptoms within the last seven days, with scores of 0 if symptoms 
are not present, 1 if present at least once in the last 30 days or up to 5 days a week, and 2 if 
present 6 or 7 days a week. 
The DRS has been correlated with the Cornell Scale for Depression (r = 0.69, P < 0.05, 
sensitivity = 78%, specificity = 77%) and the Hamilton Depression Rating Scale (r = 0.70, P < 
0.05, sensitivity = 94%, specificity = 72%)(Burrows, Morris, Simon, Hirdes & Phillips, 2000). In 
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addition, the DRS has been correlated to the NPI Depression subscale showing a significant 
correlation (p = 0.41, P = .040), and NPI total score (p = 0.42, P = .038), with a sensitivity = 
0.44, a specificity = 0.71, a PPV = 0.80, and a NPV = 0.33 (Smart, Herrmann, & Lanctot, 2011). 
When compared to the DSM-IV Geriatric Psychiatry Assessment, the DRS has shown sensitivity 
of 91 % and specificity of 69% (Burrows et al., 2000). While the DRS has been significantly 
correlated to these scales, it has been found that the DRS may have difficulty detecting mild 
depressive symptoms in those with severe dementia (Smart, Herrmann, & Lanctot, 2011). This 
has been suggested due to the difficulty this population can have with verbally communicating 
symptoms and the fact that 3 of 7 items on the DRS scale are related to speech. 
Mortality Indicators 
Mortality data was provided within the RAI, DAD and NACRS datasets. 
Antipsychotic Medication Use 
The MDS 2.0 records the frequency of usage per week during the preceding measurement 
period. Previous findings suggest that the vast majority of residents administered antipsychotics 
receive daily use (Stones, Stewart & Kirkpatrick, 2003). 
Analyses 
Descriptive statistics obtained for all the preceding measures include graphical and 
tabular trends. This included information related to the measures such as gender or age, type of 
facility resided in, and antipsychotic medication use. The main analyses made use of binomial 
logistic mixed modeling from the SPSS 2.0 generalized linear mixed model battery. The reasons 
for this form of analysis include (a) non-independence of observations from residents within the 
same facilities, (b) non-normal distributions for the dependent variables, and (c) capability to 
take account of missing data. Due to the dependence of observations within facilities, as shown 
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later on, and because of non-normal distributions, conventional types of tests such as t-tests, chi 
squares, and analyses of variance inappropriate. 
The generalized linear mixed models were hierarchical, with mortality being the target 
variable. Initial models included demographics, such as age, gender, and type of facility (CCC, 
LTC), as covariates and time of measurement as a categorical variable (with the intake 
assessment as reference category). Subsequent models sequentially included MDS 2.0 outcome 
measures, diagnostic variables, change in MDS 2.0 outcomes over time, and antipsychotic 
medication use. All the models included facilities as a random intercepts (given that residents are 
grouped by facility) and measurement periods as random slopes. The random covariance 
matrices will be unstructured. All continuous variables were centred on grand means. 
Antipsychotic medication use was measured in two ways, based on change in use over time and 
percent of daily occurrences. The antipsychotic medication variable measuring change in use 
over time contained nine levels, based on the participant either using the medication every day, 
inconcsistently throughout the week (medically termed pro re nata)(PRN), or none at all. 
Antipsychotic medication use on initial assessment was then matched with use on the last 
assessment, for example everyday to everyday, everyday to PRN, everyday to none, and so on 
for PRN use and non use. The antipsychotic medication use variable related to percent of daily 
occurrences measured overall use based on the percent of participants who used these 
medications everyday, as a PRN, or none at all. 
Results 
Descriptives 
This section describes the trends for variables in this study through distributions. It does 
not include inferential statistics because of the possibility of correlated error within facilities. 
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Participants. There were 102,658 participants included in this study over the two years 
of data collection. 
Gender. There were three gender categories included in this study, based on the 
information contained on the MDS assessments: male, female, and other. Females made up 
69.1% (N = 70,961) of participants, while 30.8% (N = 31,628) were males, and 0.1% (N = 69) 
were classified as ‘other’. It is believed that the classification of ‘other’ may have been used 
when a gender was not specified, or if the person identified as transgendered or was clinically a 
hermaphrodite. Omitting the ‘other’ gender variable would have been inappropriate due to its 
consistent usage within the data. In addition, the number of individuals classified as ‘other’ (N = 
69) was large enough to have adequate findings. 
Age. Due to the nature of the study, participants included in the analyses were 65 years 
of age and older. The average age of participants was 84.2 years (SD = 7.72), ranging from 65 to 
114 years (median = 85.0, mode = 88.0)(Figure 1). Due to the wide distribution of age and 
potential differences related to older versus younger participants, such as normal variations in 
health, physical abilities and behaviour, three age categories were created to facilitate descriptive 
depiction: 65-79 (N = 26057, 25.4%), 80-89 (N = 50654, 49.3%), and 90-114 (N = 25947, 
25.3%) years. Categories were created to have a normal curve, with roughly 25 percent of 
participants falling into the first group, 50 percent into the second, and 25 percent in the third. 
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Figure 1. 
Age distribution at first assessment 
Age at Assessment 
Facilities. A higher proportion of participants resided in the 668 LTC facilities (85.7%) 
than in the 92 CCC facilities (14.3%) during the course of this study. Within these facilities, 
12.1% (N = 8570) of female participants resided in CCCs, as did 19.2% (N = 6069) of males, 
and 11.6% (N = 8) of participants classified as ‘other’. Younger participants were more likely to 
reside in CCC facilities, while older adults were more likely to reside in LTC facilities (Figure 
2). 
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Figure 2 
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Observations. The MDS 2.0 assessment is given to all LTC and CCC residents within 
14 days of initial admission to the care facility. Subsequently, the MDS 2.0 is re-administered 
on a quarterly basis, or within 14 days of transferring to a new facility. Of the 102,658 
participants in this study, the MDS 2.0 was administered an average of 5.83 times per 
participant, with a range of 1-18 times (SD = 2.878)(Table 1). 
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Table 1 
Frequency of Observations 
Observations Frequency 
1 14177 (13.8%) 
2 7574 (7.4%) 
3 6246 (6.1%) 
4 5542 (5.4%) 
5 7063 (6.9%) 
6 7301 (7.1%) 
7 7219 (7.0%) 
8 32059 (31.2%) 
9 13526 (13.2%) 
10 1692 (1.6%) 
11 186 (.2%) 
12 51 (.0%) 
13 9 (.0%) 
14 4 (.0%) 
15 2 (.0%) 
16 3 (.0%) 
17 3 (.0%) 
18 1 (.0%) 
Total 102658 (100.0%) 
MDS 2.0 Summary Scales 
Activities of Daily Living Scale (ADL). Only 7.3% of participants in this study did not 
need any support with their activities of daily living (range = 0-6)(Table 2). Over half of the 
participants (53.1%) required a moderate or higher level of support. The distribution of scores 
on this scale was negatively skewed, with a greater number of participants requiring a higher 
level of support with their activities of daily living (Figure 3). 
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Table 2 
Activities of Daily Living scores 


























Distribution of Activities of Daily Living scores 
Activities of Daily Living Scale 
Mean = 3.42 
Std. Dev. = 1 
N = 102,658 
713 
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Aggressive Behaviour Scale (ABSj. For 59.8% of individuals in this study, no ABS 
items were endorsed. A total of 90.1 % of participants received an ABS score of 4 or less, which 
is within the mild to moderate categories of aggressive behaviour (range = 0-12)(Table 3). Only 
9.9% of people received a score of 5 or more, indicating severe aggression (Figure 4). When 
looking at the differences in participants with and without dementia, those who were diagnosed 
with dementia (Table 4) were much more likely to display aggressive behaviour than those who 
were not (Table 5). Only 41.8% of individuals diagnosed with dementia displayed no aggressive 
behaviour, compared to 70.4% of those without this diagnosis. Furthermore, only 83.6% of 
people with dementia received a score on the ABS of 4 or less, compared to 95.7% of those 
without dementia. 
Table 3 
Aggressive Behaviour Scale scores 
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Figure 4 
Distribution of Aggressive Behaviour Scale scores 
Mean =1.37 
5td. Dev. = 2 
N = 102,534 
326 
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Table 4 
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Table 5 


















































Changes in Health, End-Stage Disease and Symptoms and Signs (CHESS) Scale. 
The majority of participants in this study, 44.7%, obtained a score of zero on the CHESS scale, 
indicating ‘no health instability’(range = 0-5)(Table 6). A total of 90.4% of people received a 
score of 2 or less, indicating ‘low health instability’, while the remaining 9.6% received a score 
of 3 to 5, indicating a range from ‘moderate’ to ‘very high’ health instability (Figure 5). 
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Table 6 
Changes in Health, End-Stage Disease and Symptoms and Signs Scale Scores 























Distribution of CHESS scale scores 
Mean = .94 
Std. Dev. = 1 
N = 102,658 
Changes in Health, End~Stage Disease and 
Symptoms and Signs Scale 
107 
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Cognitive Performance Scale (CPS). Only 16.7% of participants in this study had a 
score of zero on the CPS, indicating ‘intact’ cognitive abilities (Table 7). Just under half of 
people, 46.0%, received scores within the ‘mild’ cognitive impairment range or less (scores 0 - 
2) (Figure 6). In contrast, 54% of participants were classified in the ‘moderate’ to ‘very severe’ 
range of cognitive impairment (scores 3 - 6). 
Table 7 
Cognitive Performance Scale scores 
Scale Scores 
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Figure 6 
Distribution of Cognitive Performance Scale scores 
Nfean = 2.63 
Std. Dev. = 1.834 
N = 102,658 
Cognitive Performance Scale 
Depression Rating Scale (DRS). Of the participants included in this study, 66.7% 
obtained a score of 0 - 2, indicating no significant level of depression (range = 0-14)(Table 8). 
The subsequent 33.3% of participants had a score of 3 - 14 which indicates minor to major 
depressive disorders (Figure 7). There was no substantial difference between depression rates in 
those with (Table 9) or without a diagnosis of dementia (Table 10). A graph is included to 
visually show the difference depression rates for those with and without (Figure 8). 
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Table 8 
Depression Rating Scale scores 
Scale Scores Frequency  
0 33523 (32.7) 
1 16544 (16.1) 
2 18280 (17.8) 
3 10018 (9.8) 
4 8731 (8.5) 
5 4872 (4.7) 
6 4060 (4.0) 
7 2315 (2.3) 
8 1778 (1.7) 
9 943 (.9) 
10 735 (.7) 
11 321 (.3) 
12 263 (.3) 
13 85 (.1) 
14 66 (.1) 
Total 102534 (99.9) 
Missing 124 (.1) 
Total 102658 (100.0) 
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Table 9 
Depression Rating Scale scores with dementia 
Scale Scores Frequency  
0 17029 (28.3) 
1 9997 (16.6) 
2 11796 (19.6) 
3 6229 (10.4) 
4 5457 (9.1) 
5 3034 (5.0) 
6 2467 (4.1) 
7 1462 (2.4) 
8 1120 (1.9) 
9 612 (1.0) 
10 433 (.7) 
11 212 (.4) 
12 163 (.3) 
13 50 (.1) 
14 35 (.1) 
Total 60096 (99.9) 
Missing 60 (.1) 
Total 60156 (100.0) 
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Table 10 
Depression Rating Scale scores without dementia 
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Figure 7 
Distribution of Depression Rating Scale scores 
Mean = 2.16 
Std.Dev. = 2.397 
N = 102,534 
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Figure 8 
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Antipsychotic Medication Use 
Participants. Of the 102,658 participants included in this study, 31,803 (31%) people 
were on an antipsychotic medication at least once per week, with the majority of those (29.2%) 
receiving these medications 7 days per week (Table 11). 
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Table 11 





























Gender. Males were prescribed antipsychotic medications more than females, with 
31.1 % of males receiving these medications seven days a week, while the same can be said for 
29.0% of females (Figure 9). Consistent with this finding, 69.4% of females did not take 
antipsychotic medications compared to 67.0% of males. Those participants whose gender was 
classified as ‘other’ had the highest rate of antipsychotic medication use, with 33.0% of these 
participants taking them seven days a week. 
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Figure 9 
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Age. Younger people were more likely to be prescribed antipsychotic medications, than 
those in the older age categories (65-79 = 34.5%; 80-89 = 29.8%; 90-114 = 22.9%) (Table 12). 
This observation is also most prevalent when looking at those participants who were prescribed 
an antipsychotic medication for either 0 or 7 days out of the week. Gender differences in the rate 
of antipsychotic medication use are also shown to diminish with age (Figure 10). 
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Table 12 
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Facility. Participants residing in LTC facilities (31.0%) were more likely to be 
prescribed antipsychotic medications seven days a week than those living in CCC (18.7%) 
facilities (Table 13). This was true for both males and females; however, there was a reduction 
in antipsychotic medication use for those with a gender classified as ‘other’ (Figure 11). 
Table 13 
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Figure 11 


























Dementia. Participants with dementia were far more likely to be prescribed 
antipsychotic medications than the general participant population. A total of 37.7% of 
participants with dementia were taking antipsychotic medications seven days a week (Table 14), 
compared to only 17.2% of those participants without a diagnosis of dementia (Table 15). Of 
participants who were taking antipsychotic medications, those with a diagnosis of dementia were 
over twice as likely to be taking these medications inconsistently throughout the week (Table 
16). 
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Table 14 
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Table 16 
Dementia and antipsychotic medication use 
Days taking Dementia Diagnosis 
Antipsychotics No Yes Total  
ODays 34606 (48.8%) 36236 (51.2%) 70842 (100%) 
1-6 Days 560 (31.2%) 1234 (68.8%) 1794 (100%) 
7 Days 7314 (0.2%) 22686 (75.6%) 30000 (100%) 
When looking at cognitive impairment using the CPS scores, regardless of a diagnosis of 
dementia, it was found that 74.1 % of individuals with moderate to severe cognitive impairment 
were taking antipsychotic medications at least once a week, compared to only 14.5% with mild 
impairment, with 69.6% taking them 7 days a week (Table 17). Results also show that of all the 
people taking antipsychotic medications in this study 7 days a week, 89.1% were classified as 
having moderate to severe cognitive impairment. 
Table 17 






1 - 6 Days 
7 Days 
Total 
20355 (85.5%) 34241 (66.3%) 
167 (0.7%) 872 (1.7%) 
3278 (13.8%) 16494 (32.0%) 





Aggressive behaviour. Aggressive behaviour was analyzed using ABS scores, 
distributing them between mild, moderate, and severe categories. It was shown that 60.1% of 
participants with severe aggression took antipsychotic medications 7 days a week, as did 50% of 
those with moderate aggression, and 25% of those with mild aggression (Table 18). Only 35.7% 
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of participants with severe aggression did not take any form of antipsychotic medication. 
Table 18 
Level of aggression and antipsychotic medication use 
Days taking 
Antipsychotics Mild 
Level of Aggression 
Moderate Severe 
0 Days 
















Of the 102,658 participants in this study, 32.2% (N = 33,071) died during the data 
collection period. Those classified with a gender of ‘other’ had the highest rate of death during 
the study at 39.1%, followed by males, 35.3%, and then females, 30.8% (Table 19). 
Table 19 
Rate of overall death based on gender 
Survival Gender 
 Female Male Other  
Alive 49088 (69.2%) 20457 (64.7%) 42 (67.8%) 
Deceased 21873 (30.8%) 11171 (35.3%) 27 (32.2%) 
Total 70961 (100%) 31628 (100%) 69 (100%) 
Substantially more people died in CCC facilities (43.8%) during this study, than in LTC 
facilities (30.8%)(Table 20). There was a small difference in rate of death during this study 
between those with (33.6%) and without (30.3%) a diagnosis of dementia (Table 21). 
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Table 20 
Rate of overall death based on facility 
Survival Facility 
 CCC LTC  
Alive 6097 (56.2%) 63490 (69.2%) 
Deceased 4748 (43.8%) 28323 (30.8%) 
Total 10845 (100%) 91813 (100%) 
Table 21 
Rate of overall death for participants with and without dementia 
Survival Dementia Diagnosis Total 
 No Yes  
Alive 29608 (69.7%) 39973 (66.4%) 69581 (67.8%) 
Deceased 12872 (30.3%) 20183 (33.6%) 33055 (32.2%) 
When looking at participant deaths in relation to antipsychotic medication use, there was 
a large difference in death rate based on the frequency of dispensation of these medications 
within a one week period (Table 22). Participants who took these medications inconsistently 
throughout the week (1-6 times per week) had a higher rate of death (61.2%) than those 
participants who were not on this type of medication at all (32.2), while participants who were 
taking antipsychotic medications seven days a week were the least likely to die (30.4%)(Figure 
12). This pattern was the same for those with (Table 23) and without (Table 24) dementia. 
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Table 22 














48011 (67.8%) 22844 (32.2%) 
247 (46.6%) 283 (53.4%) 
118 (40.3%) 175 (59.7%) 
89 (34.4%) 170 (65.6%) 
67 (30.3%) 154 (69.7%) 
71 (32.3%) 149 (67.7%) 
104 (38.4%) 167 (61.6%) 
20880 (69.6%) 9129 (30.4%) 
69587 (67.8%) 33071 (32.2%) 
Figure 12 
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Table 23 
Rate of death for those using antipsychotic medications with dementia 
Days taking Died 
Antipsychotics No Yes Total  
ODays 23793 (65.7%) 12443 (34.3%) 36236 (100.0%) 
l-6Days 503 (40.8%) 731 (59.2%) 1234 (100.0%) 
7 Days 15677 (69.1%) 7009 (30.9%) 22686 (100.0%) 
Table 24 
Rate of death for those using antipsychotic medications without dementia 
Days taking Died 
Antipsychotics No Yes Total  
ODays 24214 (70.0%) 10392 (30.0%) 34606 (100.0%) 
1-6 Days 193 (34.5%) 367 (65.5%) 560 (100.0%) 
7 Days 5201 (71.1%) 2113 (28.9%) 7314 (100.0%) 
Generalized Linear Mixed Modeling. Generalized linear mixed modeling was used to 
explore the relationship between the use of antipsychotic medications and overall death within 
different contexts. Initially, a series of six models were developed to serve as the foundation to 
explore these relationships, which were then manipulated depending on the context that was 
being explored. Eight contexts were explored using these models providing a thorough 
examination of the relationship between antipsychotic medications and death within this data set. 
To aid in clarity, only the final complete model will be reported for these eight contexts. 
GLMM set one - All participants. The preliminary series of six models were 
developed to build on one another. All models used the facilities participants resided in as a 
random variable, due to the similarities found when people live in the same residence (e.g. same 
staff, nutritional/recreational options, medication protocols). Sector (ETC or CCC) was used as a 
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fixed variable. The death related variable, died, was entered as the target dependent variable. 
The distribution for the dependent variable in this series of models was interval censored 
survival, which uses a binomial distribution with a complementary log-log link. This type of 
distribution has been shown to be useful in survival analyses, such as the ones in the current 
study, when some participants do not die during the study period (Douglas & Homan, 1998). All 
continuous variables used within the models in this study were centred on their grand means, in 
order to give results consistent meaning. 
The first set one model, the null model, was run using the information above, with no 
added fixed effects. The purpose of this model was to provide a base measure for all subsequent 
models. All participants were included in this model. It was found that the overall correct 
classification for this model was 68.1%. The random variable of facility had a significant effect 
on the death rate (Wald Z = 14.610,/? <.001)(Table 25). 
Table 25 
GLMM set one - null model intercept 
Random Effect 95 % Confidence 
Covariance Estimate Std. Error Z Sig. Lower Upper 
Intercept ^97 .007 14.610 .000 .085 .111 
The next model. Model 2, was built using the null model as a foundation while also 
including demographic information on participants. Overall correct classification went up to 
68.9% (Wald Z = 14.401,/? < .001)(Table 26). Demographic variables included participants’ age 
at assessment, gender, and whether they resided in a ETC or CCC facility. This model showed 
that older individuals had a greater chance of dying, as did those living in CCC (Table 27). 
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Males had a higher death rate than females as did participants who had a gender classified as 
‘other’. 
Table 26 
GLMM set one - model 2 intercept 
Random Effect 
Covariance Estimate Std. Error Sig. 
95% Confidence 
Lower Upper 
Intercept .092 .006 14.401 .000 .081 .106 
Table 27 
GLMM set one - model 2 





Gender - Other 
Gender - Male 






























Model 3 was then built to include the variables in model 2, with the addition of the MDS 
Summary Scales as fixed effects. These five scales, ABS, ADL, CPS, CHESS, and DRS, 
increased the overall correct classification to 72.4% (Wald Z = 14.244, p < .001)(Table 28). 
Results from this model showed that participants who had higher scores on these scales (had 
more/worse symptoms), except for the ABS, had a higher rate of death than those who did not 
(Table 29). Unlike the other MDS scales, ABS score was found not to be related to rate of death. 
In addition, when the MDS Summary Scales are added to the model, the difference in death rate 
between those living in LTC and CCC loses significance {p > .05) (Table 29). 
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Table 28 
GLMM set one - model 3 intercept 
Random Effect 
Covariance Estimate Std. Error 
95% Confidence 
Lower Upper 
Intercept .095 .007 14.244 .000 .082 .109 
Table 29 
GLMM set one - model 3 





Gender - Other 
Gender - Male 






































































The next model, model 4, was built by adding diagnostic variables as additional fixed 
effects. These variables related to manic depression, schizophrenia, cancer, and dementia 
increased the overall correct classification to 72.7% (Wald Z = 14.154, p < .001)(Table 30). 
Surprisingly, this model indicated that those participants who had a diagnosis of manic 
depression, schizophrenia, or dementia had lower rates of death than those participants without 
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such a diagnosis’ (Table 31). Those with a diagnosis of cancer had a higher rate of death than 
those participants without this diagnosis. When the diagnostic variables were added to the 
model, the difference in death rate for participants residing in LTC or CCC returned, with those 
living in CCC facilities having an increased risk for death (/? < .01). 
Table 30 
GLMM set one - model 4 intercept 
Random Effect 95% Confidence 
Covariance Estimate Std. Error Z Sig. Lower Upper 
Intercept ^94 .007 14.154 .000 .081 .107 
1 It is possible that the lower death rate for dementia may be due to shared variance with the CPS. 
Analysis that omitted the CPS as a fixed effect showed a significantly higher death rate for 
residents with dementia (p < .05). 
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Table 31 
GLMM set one - model 4 





Gender - Other 
Gender - Male 












Cancer - Yes 
Cancer - No 
Schizophrenia - Yes 
Schizophrenia - No 
Dementia - Yes 




















































































.001 -.256 -.065 
.000 -.123 -.069 
The change in MDS Summary Scale scores over time was added next to the series of set 
one models, in model 5. This increased the overall correct classification of the model to 77.7% 
(Wald Z = 14.367, p < .001)(Table 32). A change in scores over MDS assessments appears to 
reduce death rate for those participants with changes in their CPS and ABS scores, while 
increasing the risk for death for those with changes in their CHESS score (Table 33). No 
significant relationship was found for rate of death due to change in ADL or DRS scores. After 
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adding the change in MDS Summary Scale scores to the model, the risk of death for those 
individuals diagnosed with schizophrenia lost significance (p > .05), and became equivalent to 
those who were not diagnosed with this disorder. 
Table 32 
GLMM set one - model 5 intercept 
Random Effect 95% Confidence 
Covariance Estimate Std. Error Z Sig. Lower Upper 
Intercept .107 .007 14.367 .000 .093 .123 
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Table 33 
GLMM set one - model 5 





Gender - Other 
Gender - Male 












Cancer - Yes 
Cancer - No 
Schizophrenia - Yes 
Schizophrenia - No 
Dementia - Yes 





























































































































The Final Model was created to include the change in antipsychotic medication use over 
assessments. This increased the overall correct classification to 77.8% (Wald Z = 14.366, p < 
.001)(Table 34). A change in the frequency of receiving antipsychotic medications was a risk 
factor for death in participants who were receiving no antipsychotic medications and then started 
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as a PRN, those who stayed on antipsychotics as a PRN, and those who were taking 
antipsychotics everyday and reduced their use to an as needed basis (PRN)(Table 35). A 
decrease for risk of death occurred for individuals who went from using antipsychotics from 
everyday to none, and vise versa, as well as those who moved away from PRN use to either 
taking this medication everyday or not at all. 
Table 34 
GLMM set one -final model intercept 
Random Effect 95% Confidence 
Covariance Estimate Std. Error Z Sig. Lower Upper 
Intercept .107 .007 14.366 .000 .093 -123 
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Table 35 
GLMM set one -final model 




Gender - Other 
Gender - Male 










Manic Depression No 
Cancer - Yes 
Cancer - No 
Schizophrenia - Yes 
Schizophrenia - No 
Dementia - Yes 






Everyday to Everyday 
Everyday to PRN 
Everyday to None 
PRN to Everyday 
PRN to PRN 
PRN to None 
None to Everyday 
None to PRN 
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GLMM set two - More than one assessment. GLMM set two was run using the same 
pattern as the preliminary models, however, only included participants who had more than one 
assessment within the database. Therefore, individuals that were included in this analysis had 
two or more completed MDS assessment entries. Examining the models with only participants 
with more than one entry provides longitudinal information as it removes individuals who only 
had one record, due to situations such as death or moving to a private residence to die. 
Using only participants with more than one observation increased the overall correct 
classification of the final model from 77.8% in the preliminary model set to 79.5% (Wald Z = 
13.941, /? < .OOlXTable 36). When examining the differenees between the preliminary model 
and current model, it was found that those individuals who had their gender classified as other 
no longer had a significantly higher death rate than females (Table 37). In turn, it also showed 
that those participants who had a change in CPS score had a higher death rate than those who did 
not (p < .05), while those with a change in ABS score were no longer significantly different than 
those who did not (p > .05). The final difference between these two models was that those 
participants were maintained their use of antipsychotics as a PRN throughout their assessments, 
were no longer at an increased risk of death than those who were not taking these medications (p 
> .05). 
Table 36 
GLMM set two -final model 
Random Effect 95% Confidence 
Covariance Estimate Std. Error Z Sig. Lower  
Intercept .124 .009 13.941 »000 .\A2 
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Table 37 
GLMM set two -final model 





Gender - Other 
Gender - Male 










Manic Depression No 
Cancer - Yes 
Cancer - No 
Schizophrenia - Yes 
Schizophrenia - No 
Dementia - Yes 






Everyday to Everyday 
Everyday to PRN 
Everyday to None 
PRN to Everyday 
PRN to PRN 
PRN to None 
None to Everyday 
None to PRN 
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GLMM set three - New admissions. GLMM set three was run using only individuals 
who were new to the data set during the study period, using the same pattern as the preliminary 
models. Therefore, only individuals who were new admissions to either CCC or LTC facilities 
during the study period, and not those who were already residing in these facilities when the 
study began, were included in these analyses. This allows us to look at census level new 
admissions across all CCC and LTC facilities in Ontario, reducing potential confounds such as 
reporting differences between facilities. 
When this model was run using only individuals who were new admissions to CCC and 
LTC facilities during the study period, it was found that the overall correct classification of the 
final model increased from 77.8% in the preliminary model set to 80.5% (Wald Z = 9.057, p < 
.001)(Table 38). When looking at the differences between the preliminary model and current 
model, it was found that in relation to risk of death, significance was lost for those participants 
who had a gender marked as ‘other’, had a higher DRS score, were diagnosed with a manic 
depressive disorder, had a change in their ABS score over time, and those who went from taking 
antipsychotic medications everyday to using them as a PRN {p > .05)(Table 39). In contrast, 
there was a significant decrease risk of death for those participants who had a change in their 
DRS score over time (p < .05). 
Table 38 
GLMM set three -final model intercept 
Random Effect 95% Confidence 
Covariance Estimate Std. Error Z Sig. Lower Upper 
Intereept TIO .012 9.057 .000 .089 .137 
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Table 39 
GLMM set three - final model 





Gender - Other 
Gender - Male 










Manic Depression No 
Cancer - Yes 
Cancer - No 
Schizophrenia - Yes 
Schizophrenia - No 
Dementia - Yes 






Everyday to Everyday 
Everyday to PRN 
Everyday to None 
PRN to Everyday 
PRN to PRN 
PRN to None 
None to Everyday 
None to PRN 
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GLMM set four - New admissions and more than one assessment. GLMM set four 
was run using only individuals who were new to the data set during the study period and had 
more than one assessment, using the same pattern as the preliminary models. Therefore, only 
individuals who were new admissions to either CCC or LTC facilities during the study period, 
not those who were already residing in these facilities when the study began, and also had two or 
more assessments completed, were included in these analyses. This allowed us to look at census 
level new admissions across all CCC and LTC facilities in Ontario, who were in the study long 
enough to provide some longitudinal information. 
When this model was run using only individuals who were new admissions to CCC and 
LTC facilities and had more than one assessment during the study period, it was found that the 
overall correct classification of the final model increased from 77.8% in the preliminary model 
set to 83.6% (Wald Z = 7.470, p < .001)(Table 40). Many variables in this model lost 
significance when looking at increased death rate, when compared to the preliminary model (p > 
.05), including the increased risk for those having a gender marked as ‘other’, the difference 
between CCC and LTC facilities, having a higher DRS score, being diagnosed as having a manic 
depressive disorder, and having a change in ABS scores over assessments (Table 41). In 
addition, all variables related to taking antipsychotic medications were found to be not 
significant in this model, with the exception of changing from not taking an antipsychotic to 
taking one as a PRN showed to increase the risk of death (p < .001). The last difference for this 
final model, when compared to the preliminary final model, was an increased risk of death for 
those individuals with a higher CPS score (p < .05). 
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Table 40 
GLMM set four -final model intercept 
Random Effect 95% Confidence 
Covariance Estimate Std. Error Z Sig. Lower Upper 
Intercept 421 .016 7.470 .000 .093 457 
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Table 41 
GLMM set four - final model 





Gender - Other -12.644 
Gender - Male .279 
Gender - Female 0 
CCC -.001 
LTC 0 
ADL Scale .328 
ABS Scale .005 
CHESS Scale .630 
CPS Scale .041 
DRS Scale .007 
Manic Depression -.166 
Yes 
Manic Depression No 0 
Cancer-Yes .420 
Cancer - No 0 
Schizophrenia - Yes -.092 
Schizophrenia - No 0 
Dementia-Yes -.121 
Dementia - No 0 
ADL Change .313 
ABS Change -.011 
CHESS Change .523 
CPS Change .029 
DRS Change .000 
Everyday to Everyday .053 
Everyday to PRN .235 
Everyday to None .047 
PRN to Everyday -.173 
PRN to PRN -.103 
PRN to None -.135 
None to Everyday -.049 
None to PRN .522 
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GLMM set five - Dementia. GLMM set five was run using only individuals who were 
diagnosed with dementia. Therefore, individuals who had a diagnosis of manic depression, 
cancer, or schizophrenia were eliminated from this analysis. As people with these disorders are 
also commonly prescribed antipsychotic medications, removing them from this analysis allowed 
us to look specifically at the effects of antipsychotic medications on those participants with 
dementia. 
When this model was run using only participants with dementia, it was found that the 
overall correct classification of the final model decreased from 77.8% in the preliminary model 
set to 76.4% (Wald Z = 12.047, p < .001)(Table 42). This result showed that the fit of this 
model was not as good when using only individuals who had a diagnosis of dementia. Three 
variables lost significance in this model, when compared to the preliminary model. When 
looking at the current model, the variables related to participants who had a gender classified as 
‘other’, had a change in their ABS score, and those who were not on antipsychotics and then 
started taking them on a PRN basis, were no longer at an increased risk of death, as was the case 
in the preliminary model (Table 43). 
Table 42 
GLMM set five - final model intercept 
Random Effect 95% Confidence 
Covariance Estimate Std. Error Z Sig. Lower Upper 
Intercept .108 .009 12.047 .000 .092 -127 
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Table 43 
GLMM set five - final model 





Gender - Other 
Gender - Male 



















Everyday to PRN 
Everyday to None 
PRN to Everyday 
PRN to PRN 
PRN to None 
None to Everyday 
None to PRN 
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GLMM set six - Dementia and new admissions. GLMM set six was run using the same 
pattern as the preliminary models, however, only included participants who had a diagnosis of 
dementia, and had more than one assessment within the database. Therefore, individuals that 
were included in this analysis had dementia with two or more completed MDS assessment 
entries. Examining the models with only participants with dementia and more than one 
assessment entry provided longitudinal information as it removed individuals who only had one 
record, as well as helped to remove potential confounds related to participants taking 
antipsychotic medications for reasons other than managing symptoms related to dementia. 
Using only participants with dementia and more than one assessment increased the 
overall correct classification of the final model from 77.8% in the preliminary model set to 
78.1% (Wald Z = 13.941, < .001)(Table 44). When comparing the variables in the 
preliminary final model to this one, three variables lost significance. It was found that when 
looking specifically at participants with dementia who had more than one assessment completed, 
a change in the ABS score was no longer significant, nor was staying on an antipsychotic 
medication as a PRN across assessments, or reducing the use of an antipsychotic medication 
from a PRN to not using one at all (Table 45). 
Table 44 
GLMM set six -final model intercept 
Random Effect 95% Confidence 
Covariance Estimate Std. Error Z Sig. Lower Upp^r 
Intercept .125 .011 11.838 .000 .106 .147 
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Table 45 
GLMM set six -final model 





Gender - Other 
Gender - Male 



















Everyday to PRN 
Everyday to None 
PRN to Everyday 
PRN to PRN 
PRN to None 
None to Everyday 
None to PRN 
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GLMM set seven - Dementia with more than one assessment GLMM set seven was 
run using the same pattern as the preliminary models, however, only included participants who 
had a diagnosis of dementia, and were classified as a new admission within the database. 
Therefore, individuals that were included in this analysis had dementia and entered a CCC or 
LTC facility after the study had begun. Examining the models with only participants diagnosed 
with dementia who were new admissions provides a consistent and complete picture of residents 
with dementia in CCC and LTC facilities, as it helped reduce reporting differences seen prior to 
the MDS assessments becoming mandatory in all facilities in Ontario. 
Using only participants with dementia who were new admissions to CCC and LTC 
facilities increased the overall correct classification of the final model from 77.8% in the 
preliminary model set to 80.0% (Wald Z = 6.009, p < .001)(Table 46). Several variables lost 
significance for risk of death in this model when compared to the final preliminary model, 
including those participants with a gender classified as ‘other’, a high DRS score, and a change 
in ABS score (Table 47). In addition, participants who switched from taking antipsychotic 
medication everyday to PRN use, and those who went from taking them as a PRN to not at all, 
and vise versa, were not significantly different than those who not prescribed these medications. 
Table 46 
GLMM set seven - final model intercept 
Random Effect 95% Confidence 
Covariance Estimate Std. Error Z Sig. Lower Upper 
Intercept .113 .019 6.009 .000 .082 .157 
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Table 47 
GLMM set seven - final model 





Gender - Other 
Gender - Male 



















Everyday to PRN 
Everyday to None 
PRN to Everyday 
PRN to PRN 
PRN to None 
None to Everyday 
None to PRN 
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GLMM set eight - Dementia and new admissions and more than one assessment. 
GLMM set eight was run using the same pattern as the preliminary models, however, only 
included participants who had a diagnosis of dementia, were classified as a new admission 
within the database, and had more than one assessment. Therefore, individuals that were 
included in this analysis had dementia, entered a CCC or LTC facility after the study had begun, 
and had two or more assessments completed. Analyzing the models this way allowed for a very 
elean and specific view of census level CCC and LTC facility admissions across Ontario for 
those diagnosed with dementia over time. 
When this model was run using only individuals diagnosed with dementia, who were new 
admissions to CCC and LTC facilities, and had more than one assessment during the study 
period, it was found that the overall correct classification of the final model increased from 
77.8% in the preliminary model set to 83.6% (Wald Z = 5.317, p < .001)(Table 48). Many 
variables lost significance in this model, when compared to the final preliminary model. Having 
a gender classified as ‘other’, residing in a CCC rather than a LTC, having a high DRS score, or 
having a change in ABS score, no longer changed the risk of death for partieipants (Table 49). 
In addition, all variables related to antipsychotic medication use lost significance when looking 
at risk of death, except for those participants who went from not using this type of medication to 
using it as a PRN. These participants still had a significantly increased risk for death compared 
to those who were not using these medications at all. It must be noted that findings in this table 
(49) may be inflated due to the unusual sex distribution. 
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Table 48 
GLMM set eight -final model intercept 
Random Effect 95% Confidence 
Covariance Estimate Std. Error Z Sig. Lower Upper 
Intercept .128 .024 5.317 .000 .088 • 184 
Antipsychotic Medications and Dementia 106 
Table 49 
GLMM set eight -final model 





Gender - Other 
Gender - Male 



















Everyday to PRN 
Everyday to None 
PRN to Everyday 
PRN to PRN 
PRN to None 
None to Everyday 
None to PRN 
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GLMM set nine - Antipsychotic medication categories. GLMM set nine was run using 
all participants, however, instead of looking at the change in antipsychotic medication use, the 
frequency of antipsychotic medication use was analyzed. For this purpose, frequency of 
antipsychotic medication use was broken down into three categories: 1. daily use (7 days per 
week), 2. used as a PRN (1 to 6 days per week), or 3. no use (0 days per week). The measure 
was the proportion of assessments per person that fell into each category. This analysis provided 
a picture of whether there was a difference in death based on whether these medications were 
used, not used, or used as a PRN. 
When this model was run using the variables related to the categories of antipsychotic 
medication use, it was found that the overall correct classification of the final model decreased 
from 77.8% in the preliminary model set to 77.7% (Wald Z = 14.363, p < .001)(Table 50). This 
result showed that the fit of this model was not as good as when the change of antipsychotic 
medication was analyzed. With that being said, no variables lost significance in this model, and 
it was shown that those participants who were taking antipsychotic medications as a PRN or 
daily had a lower risk of death then those participants who were not taking them at all (Table 
51). This result may be due to confounds related to the prescribing of antipsychotic medications 
to help manage symptoms of other illnesses. 
Table 50 
GLMM set nine - final model intercept 
Random Effect 95% Confidence 
Covariance Estimate Std. Error Z Sig. Lower Upper 
Intercept .107 .007 14.363 .000 .093 .122 
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Table 51 
GLMM set nine - final model 
Model Term Coefficient Std. Error 
Intercept 
Age 
Gender - Other 
Gender - Male 












Cancer - Yes 





Dementia - Yes 
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Discussion 
The current study provides the most comprehensive look at the current use of 
antipsychotic medications in older adults residing in CCC and LTC facilities in Canada, with 
specific attention given to those individuals diagnosed with dementia. This study is the first to 
provide census level data for this type of information across Ontario for all continuing care 
facilities using the MDS 2.0, NACRS, and DAD databases. Having this level of data allows for a 
complete view of the effects antipsychotic medications have in this population, which has never 
been seen before. This study was completed with the goals of providing information regarding, 
1) the nature of older adults living in CCC and LTC facilities; 2) the use of antipsychotic 
medications in these facilities, with specific reference to those individuals diagnosed with 
dementia or who were exhibiting aggressive behaviour; and 3) whether taking antipsychotic 
medications increased the risk of mortality in older adults. 
Resident information for CCC and LTC facilities 
There were more than 100,000 individuals, age 65 and older, living in residential care 
facilities in Ontario during the study period. Females made up approximately two thirds of this 
population (69.1%), while males made up the rest (30.8%), with the exception of 69 individuals 
(0.1%) who were classified as ‘other’. It is surmised that for those individuals who had a gender 
was classified as ‘other’, it was either due to a data collection error by the residential facility, the 
participant may have identified as transgendered, or was clinically a hermaphrodite. The average 
age of participants included in the study was 84.2 years, ranging from 65 to 114 years old. 
The majority of individuals in this study resided in LTC (85.7%) facilities compared to 
CCCs (14.3%). Males (19.2%) were more likely to live in CCCs then females (12.1%), and 
those living in CCCs were typically younger than people living in LTC facilities. It is believed 
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that individuals in CCCs were younger due to the nature of care within these facilities compared 
to LTCs. CCCs are hospital-based facilities that would typically provide care for individuals 
suffering from issues related to acute illnesses and events (e.g. heart attack), surgery, or 
rehabilitation (e.g. strokes), while patients with chronic and progressive illnesses are more likely 
to reside in LTC facilities (e.g. Parkinson’s disease, cognitive decline). While living in these 
facilities, the average person was assessed using the MDS 2.0 approximately 8 times (31.2%), 
with a range of 1 to 18 assessments. 
The MDS 2.0 summary scales provided valuable information regarding the functional 
abilities of individuals living in CCC and LTC facilities. Very few individuals residing in these 
facilities did not require any support with their activities of daily living (7.3%). Over half 
(53.1%) of the participants in the study required a moderate or higher level of support in order to 
successfully make it through their day. 
Approximately 60% of people in this study did not exhibit any aggressive behaviours in 
CCC and LTC facilities, while 90% displayed aggression at moderate or lower levels. Only 10% 
of individuals in these facilities displayed severe aggression. This picture is quite different when 
looking at the differences in aggressive behaviour for those individuals with and without a 
diagnosis of dementia. Almost 60% of participants in the study who were diagnosed with 
dementia showed at least a minimal level of aggression compared to 30% of those without this 
diagnosis. 
When looking at severe aggression in those with dementia, the rate drops dramatically to 
only 12.5% of individuals exhibiting these behaviours, and 3% for those without dementia. 
While the total of aggressive behaviour is far above the findings in previous studies relating to 
dementia patients, with 20% to 50% exhibiting this behaviour in community samples (Jost & 
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Grossberg, 1996; Lyketsos et al., 2000), it is quite a bit lower when only looking at severe 
aggression. It may be that the difference in this high number of aggressive behaviour is due to 
the admitting practices and protocols of residential facilities in Canada, where all attempts are 
typically made to keep individuals out of residential care until absolutely necessary. Due to this, 
a trend may be seen that most individuals admitted to a CCC or LTC facility would be displaying 
more significant symptoms than those with dementia still living in the community, even though 
they are not necessarily considered ‘severe’. 
While participants in this study may have been showing a higher level of aggressive 
symptoms than those still residing in the community, the CHESS scale showed that the majority 
of participants (90.4%) had very low physical health instability. Only 9.6% of people in these 
facilities had moderate to very high health instability. Cognitively, results showed through the 
CPS that 54% of participants had moderate to very severe cognitive impairment, only 
approximately 17% had intact cognitive abilities. The results in this current study indicate that 
while physical health may be generally good in older adults residing in CCC and LTC facilities, 
cognitive decline and impairment are more common than not. 
Approximately one third of participants in this study also had symptoms of depression 
ranging from minor to major, according to the DRS. There was not a substantial difference in 
symptoms of depression level for those with (35.4%) or without dementia (30.4%), when looking 
at scores 3 and above, indicating minor to major depressive issues. While this finding contrasts 
the International Psychogeriatric Association’s (2002) finding that up to 80% of individuals with 
dementia suffer from symptoms of depression within the course of their illness, it may be 
consistent with their assertion that symptoms of depression are more prevalent in the early and 
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middle stages of dementia and cognitive impairment, as people in CCC and LTC facilities may 
be further along in their illnesses and impairment. 
Use of antipsychotic medications in CCC and LTC facilities 
Past research has indicated that approximately 40% to 50% of residents residing in CCC 
and LTC facilities were being prescribed antipsychotic medications (CIHI, 2009; Ministry of 
Health, 2011). This is despite the fact that research has shown the efficacy of antipsychotic 
medications in older adults with and without dementia was questionable (Ballard & Howard, 
2006; Mintzer et al., 2006; Schneider et al., 2008), and there were multiple health warnings from 
government agencies regarding an increased risk of mortality in people with dementia 
(Committee on Safety of Medicines, 2005; Federal Drug Administration, 2005; Health Canada, 
2005), as well as a plethora of other significant side effects (Ballard et al., 2005; Herrmann & 
Lanctot, 2005; Lacut et al., 2007; Trifiro et al., 2010). 
The current study indicates that 31 % of people in CCC and LTC facilities in Ontario 
were taking antipsychotic medications at least once per week, with the majority of individuals 
(29.2%) taking them seven days a week, during the study period. While this is less then what 
was indicated in past research, when looking only at individuals with a diagnosis of dementia, it 
was found that 39.8% of residents took antipsychotic medications at least once per week, with a 
total of 37.7% taking them seven days a week. This compares to only 17.2% of individuals 
without a diagnosis of dementia taking these medications seven days a week. This finding is 
consistent with the hypothesis that individuals with dementia would be more likely to receive 
antipsychotic medications than those without this diagnosis. 
Males (31.1%) and females (29.0%) were prescribed antipsychotic medications at 
roughly the same rate. A total of 33.0% of individuals with a gender classified as ‘other’ 
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received this medication. Younger individuals were much more likely to be prescribed these 
medications seven days a week, when looking at the three age categories (65-79 = 34.5%; 80-89 
= 29.8%; 90-114 = 22.9%). This may be due to greater physical impairment and decreased 
strength, leading to less physical aggression, progressively in the older age groups. Individuals 
residing in LTC facilities were much more likely to be prescribed antipsychotic medications 
(31%) seven days a week and those living in CCC facilities (18.7%), regardless of gender. 
Again, this may be attributable to the reasons behind why individuals are admitted to either a 
CCC or LTC facility, such as the nature of illness. 
When looking at cognitive impairment using the CPS in the use of antipsychotic 
medications, it was found that 74.1% of individuals with moderate to severe cognitive 
impairment were prescribed these medications, with 69.6% taking them 7 days a week. This 
compares to only 14.5% of participants with mild cognitive impairment being prescribed these 
medications. When looking at only individuals prescribed antipsychotic medications, it was 
found that a staggering 89.1% were classified as having moderate to severe cognitive 
impairment. Results are not consistent with the hypothesis that those with more severe cognitive 
impairment were prescribed antipsychotic medications less often than those with milder 
impairment. 
While the finding related to cognitive impairment and antipsychotic medication use was 
not consistent with the study hypothesis, the finding was consistent to the one related to 
aggressive behaviour. It was shown that 60.1 % of participants with severe aggression took 
antipsychotic medication seven days a week, while only 50% of those with moderate aggression, 
and 25% of those with mild aggression did so. This is despite the fact there are many studies 
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questioning the limited effectiveness and safety of using antipsychotic medications to treat 
agitation and aggression (Ballard & Howard, 2006; Schneider et ah, 2008; Sultzer et al., 2008). 
Use of antipsychotic medications and mortality risk 
Of the 102,658 individuals included in this study, 32.2% died during the data collection 
period. Those with the gender classified as ‘other’ (39.1%) had the highest death rate, followed 
by males (35.3%), and then females (30.8%). Difference in death rate for males and females 
may well be due to the fact females live longer on average. Results also showed that individuals 
living in CCC facilities (43.8) had a higher death rate than those in LTC facilities (30.8%). As 
stated earlier, CCC facilities typically admit patients with more acute health problems, such as 
heart attacks and strokes, while LTC facilities typically admit patients with chronic conditions 
such as dementia, which would explain the higher death rate in CCC facilities. 
Only one antipsychotic medication, risperidone, has been approved for the treatment of 
behavioural and psychological symptoms of dementia in Canada for, ''short-term symptomatic 
management [emphasis added] of inappropriate behaviour due to aggression and/or psychosis in 
patients with severe dementia” (Health Canada, 2005, p.l). Many quality research studies have 
shown that the use of antipsychotic medication in older adults with dementia increased overall 
mortality rate in this population (Gill et al., 2007; Health Canada, 2005; Trifiro et al., 2009; 
Musicco et al., 2011), which led to multiple warnings within Canada from drug manufacturers 
(Banjeree, 2009) and Health Canada itself (2005). 
Increased risk of death been found for both conventional and atypical antipsychotic 
medications (Wang et al., 2005; Schneeweiss et al., 2007), with research showing that elderly 
people with dementia taking an atypical antipsychotic were at a twofold risk for death, while 
those taking a conventional antipsychotic were at a fourfold risk of death, compared to controls 
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(Musicco et al., 2011). Despite this, the current study shows that almost 40% of residents in CCC 
and LTC facilities with dementia are prescribed this type of medication. 
Results from this study paint a different picture than previous research in regards to 
increased risk in overall death for older adults. Of the 102,658 participants included in this 
study, there was no substantial difference in death rate for those who were not taking this type of 
medication (32.2%) and those who were taking this type of medication seven days a week 
(30.4%). This trend for death rates related to antipsychotic medication use was similar for both 
those with dementia, 34.3% and 30.9% respectively, and those without dementia, 30.0% and 
28.9% respectively. 
An interesting finding occurred when further analysis was done to explore the rate of 
death associated with antipsychotic medications for those individuals who were taking this type 
of medication as a PRN, between 1 to 6 days a week. Those individuals who took antipsychotic 
medications infrequently throughout the week, one to six times, had a much higher rate of death 
(61.2%) than those who did not take it at all (32.2%) or took it seven days a week (30.4%). 
When looking at individuals with and without dementia the results were the same. Rate of death 
for individuals with dementia increased to 59.2% when these medications were taken as a PRN 
throughout the week, versus 30.9% when taken 7 days a week, and 34.3% when not taken at all. 
For those without dementia, death rate was 65.5% when these medications were taken 1 to 6 
times throughout the week, compared to 20.9% when taken seven days a week, and 30.0% when 
not taken it all. 
These results suggest that regardless of dementia diagnosis, the risk of increased death 
rate correlates with frequency of antipsychotic medication use when taken inconsistently 
throughout the week, rather than consistently at seven days a week. Furthermore, results actually 
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suggest that there may be a slight protective factor when older adults take these medications 
everyday, or that these two groups (PRN versus 7 days a week) are fundamentally different 
based on other factors. Overall, individuals who were not prescribed antipsychotic medications 
had a death rate 1.8% higher than those who were taking these medications seven days a week. 
These medications appear to have the most protective effect for those individuals diagnosed with 
dementia, with results showing that people with dementia who were not taking antipsychotic 
medications died at a rate of 3.4% greater than those who were taking them seven days a week. 
In relation to individuals without a diagnosis of dementia, these participants died 1.1% more 
frequently without antipsychotic medication, than while taking this medication seven days a 
week. These findings are not consistent with the study hypothesis that those individuals receiving 
antipsychotic medications will have a higher rate of mortality than those who were not. 
No other studies could be found related to the rate of death associated with the frequency 
of antipsychotic medication use in older adults with or without dementia, to help provide an 
explanation for these findings. It is surmised that the increase rate of death in those individuals 
who took antipsychotic medications 1 to 6 days a week may be related to a few different factors. 
First, antipsychotic medications are quite potent and it may be that when older adults take them 
infrequently throughout the week, their bodies are constantly trying to regulate and 
accommodate the medication and related side effects, adding stress to already potentially frail 
and compromised systems (Van Der Hooft et al., 2005). Second, the reasons behind individuals 
being prescribed these medications as a PRN inconsistently throughout the week may be the 
reason behind the increased death rate, rather than the medication itself. 
It is unclear why this study found a lower rate of death for individuals taking 
antipsychotic medications seven days a week compared to those not taking them all. It may 
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actually be that similar findings in previous studies were overlooked as the methodology only 
looked at whether participants were, or were not, taking antipsychotic medications. If there is a 
protective factor for those individuals taking antipsychotic medications seven days a week, rather 
than not at all, it is proposed that the lower rate of death in those taking antipsychotic 
medications seven days a week its due to the benefit they have on managing BPSD and other 
symptoms. 
GLMM findings 
Rate of death was explored further in this study using multilevel linear modelling. This 
provided information regarding the relationships between different variables and the rate of death 
of participants in this study, within a variety of contexts. Understanding the factors related to 
increased death rate could prove valuable to medical professionals working in CCC and LTC 
facilities, as well as physicians working with older adults with and without dementia. 
A summary table was created to provide an opportunity to view the differences of the 
final models with ease (Table 52). Using the legend below, final models can be compared in 
regards to what final models led to significance for each variable included. 
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Final Models: 
Name Description of Model 
1 All participants model 
2 More than one assessment 
3 New admissions 
4 New admissions and more than one assessment 
5 Dementia 
6 Dementia with more than one assessment 
7 Dementia and new admissions 
8 Dementia and new admissions and more than one assessment 
9 Antipsychotic medication categories 
H = Significantly higher mortality due to higher scores on the continuous variable or due to 
differences between the target and reference categories 
L = Significantly lower mortality due to lower scores on the continuous variable or due to 
differences between the target and reference categories 
. = Not included in analysis 
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Table 52 
Summary of significance for final models 
Model Term 1 8 
Percent/Intercept 
Age 
Gender - Other 
Gender - Male 








Manic Depression Yes 
Manic Depression No 
Cancer - Yes 
Cancer - No 
Schizophrenia - Yes 
Schizophrenia - No 
Dementia - Yes 






Everyday to Everyday 
Everyday to PRN 
Everyday to None 
PRN to Everyday 
PRN to PRN 
PRN to None 
None to Everyday 
None to PRN 
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Demographic Variables. The first set of models, set one, used all participants in this 
study and was used as a base to compare subsequent models, which were run using different 
contexts (e.g. new admissions, only dementia patients). After running the null model in this set 
of models, demographic characteristics were entered. It was found that when no other variables 
were included in the model, males had a higher rate of death than females, and those living in 
CCC facilities had a lower rate of death compared to those living in LTC facilities. 
MDS 2.0 Scales. Higher scores on all of these scales, except the ABS, increased the risk 
of death. As soon as these scales were included in model three, those residing in CCC facilities 
no longer had a significantly different rate of death than those residing in LTC facilities. This 
may be due to the fact that higher scores on these scales, indicating more significant levels of 
impairment, can be related to seriousness of illness. Those who are more seriously ill have a 
greater chance of residing in a CCC due to the nature of care they provide. 
Diagnostic Variables. Diagnostic variables were added next to control for confounding 
illnesses within the MDS 2.0 related to manic depression, schizophrenia, and cancer, in model 4. 
Previous research has shown that older adults with schizophrenia (Jeste & Maglione, 2013), 
bipolar disorder (Dolder & Mckinsey, 2011), and cancer (Fisch & Kim, 2004), are often 
prescribed antipsychotic medications to help control symptoms. The current study showed that 
those individuals who were diagnosed with bipolar disorder, schizophrenia, or dementia, had a 
lower death rate than did those who were not diagnosed with these illnesses. However, those 
individuals diagnosed with cancer had a higher death rate than those who did not. These 
findings were consistent for these variables in model five and the final model, when the variable 
related to antipsychotic medications was included, with the exception of schizophrenia, which 
lost its significance in model 5 and 6. The lower death rate for individuals with schizophrenia. 
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bipolar disorder, and dementia, maybe due to the potentially protective nature of antipsychotic 
medications, as discussed earlier. In contrast, these individuals’ psychiatric condition may have 
expedited their admission into a care facility, even though they were not as medically ill, as their 
clinical presentation may have been more difficult to continue managing in the home or in 
community settings. The higher rate of death for those with cancer may be attributable to the 
organic nature of this illness. 
MDS 2.0 Change Scales. Model five was developed to include variables related whether 
participants had a change in the MDS 2.0 scales over assessments. It was found that a change in 
the ADL and CHESS scales increased the rate of death of participants, while change in ABS 
score decreased the rate of death. Having a change in CPS or DRS scales was not related to 
death rate. These findings were consistent with what was seen in the final model. The finding 
that changes in the ADL and CHESS scales is related to death is consistent with previous 
research (Mor et al., 2011; Smart, Herrmann, & Lanctot, 2011). Changes in these scores most 
likely indicate that individuals are at a stage with their health that they are losing their basic 
abilities and are becoming very frail. Having a change in ABS score decreasing death rate would 
be consistent with the fact that these people are still physically healthy enough to display the sort 
of behaviour. 
Antipsychotic Medication Use. Variables related to antipsychotic medication use were 
added to the series to create the final model. These variables looked at consistent frequency of 
antipsychotic medication use over time, as well as changes in the use of antipsychotics overtime, 
in relation to rate of death. This model confirmed the results that were discussed earlier in 
relation to death rate and antipsychotic medication use. Death rate was not related to the 
everyday use antipsychotic medications, however switching from taking these medications every 
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day to inconsistently increased death rate, while switching from everyday use to none at all 
decreased death rate, when compared to those individuals who were not taking antipsychotic 
medications at all. 
In addition, when individuals switched from using antipsychotic medications as a PRN to 
taking them every day, or stop taking them all together, death rate decreased. Those who 
continued to use antipsychotic medications as a PRN were at an increased risk of death 
compared to those who were not taking at all. Lastly, it was found that individuals who were not 
taking antipsychotics and started to take them as a PRN had an increased risk of death, but those 
who went from not taking them to taking them every day had a decreased risk of death. As 
discussed earlier, it is hypothesized that these results may be due to the potential that inconsistent 
use of antipsychotic medications has a negative impact on the bodies of older adults, and may 
also be due to the reasons behind why these medications were being prescribed as a PRN. 
Context Models. This set of models was run again using eight different contexts, with 
the final models being reported from each context and compared with the first final model, which 
used all participants in this study. These contexts included all participants (set 1), individuals 
with more than one assessment (set 2), new admissions (set 3), and new admissions and more 
than one assessment (set 4). Additionally, matching models were then run for those who were 
only diagnosed with dementia (set 5), dementia and one assessment (set 6), dementia and new 
admissions (set 7), and dementia and new admissions who had more than one assessment (set 8). 
The last model (set 9) was run with all participants but used the antipsychotic medication 
categories, rather than changes to antipsychotic medications. 
The contexts using new admissions with more than one assessment, as well as those with 
dementia that were new admissions with more than one assessment, had best fit with this model. 
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both explaining 83.6% of the variance, compared to only 77.8% of variance when using all 
participants. These models may have been able to explain the most variance because they were 
the contexts contained the most complete information. For example, these contexts included 
participants that were new residents of CCC and LTC facilities once census level data was being 
collected throughout Ontario, and were also in the study long enough to have more than one 
assessment completed. It is interesting that in these contexts, and only these contexts, all of the 
variables related to antipsychotic medication use lost significance, except for those who went 
from not using these medications to using them as a PRN throughout the week, which increased 
the rate of death. No logical explanation of this could be developed. 
The context that included only participants with dementia, with no other stipulations, was 
found have the worst fit in these models explaining only 76.4% of the variance. This was 
marginally less than set one (77.8%) which used all the participants. It may be that because the 
diagnostic variables were taken out of the model, some of the sources of variance were naturally 
lost. These findings did follow the pattern found with the other matched contexts between those 
with and without dementia. 
Study Implications and Future Research 
Results from this study may have a dramatic effect on how people view the use of 
antipsychotic medications with older adults, with and without dementia, and how physicians 
prescribe them. This is the first study to look at whether there is a difference in death rate based 
on frequency of medication use for older adults taking antipsychotics. Results consistently 
showed, over different forms of analysis, that contrary to previous research, antipsychotic 
medication does not necessarily increase death rate. Rather, it only increases death rate in those 
individuals taking these medications inconsistently throughout the week, for both individuals 
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with and without dementia. Furthermore, it appears that regular use (7 days a week) of 
antipsychotic medications may actually reduce death rate when compared to individuals who are 
not taking this medication at all. This finding was the strongest for participants with dementia. 
Based on the results from this study, it is strongly advised that further research is 
conducted focusing on the differences in death rate for older adults who are 1) not taking 
antipsychotics, 2) are taking antipsychotics as a PRN, and 3) taking antipsychotics 7 days a 
week, for those with and without dementia. The purpose of this would be to confirm and expand 
this body of knowledge. If other studies find that antipsychotic medications do increase death 
rates when taken inconsistently, medical professionals will have to be informed and adjust their 
prescription and dispensing practices accordingly, in order to prevent further deaths related to a 
very easy fix. 
If it is found that results from this study are not an anomaly, and taking antipsychotic 
medications seven days a week actually reduces the risk of death compared to those not taking it 
at all, further research would need to explore the factors surrounding why this protective effect is 
occurring. This may encourage the prescription of antipsychotic medications for specific groups 
of older adults, reducing death rate in this population significantly. Of course, this would need to 
be done while monitoring quality of life as living longer can be better in most circumstances, but 
living longer in a stupor or in pain may not be. 
It may also be that taking antipsychotic medications consistently actually reduces the risk 
of other health conditions or events, such as strokes or heart attacks, hence the findings of lower 
death rates in these participants, when those using this form of medication as a PRN are factored 
out. Replicating past studies that looked at the risk of side effects in those using this medication, 
as a PRN and seven days a week, would be highly beneficial. This will help show whether using 
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this medication as a PRN also induces more side effects, than when it is used consistently, as was 
the case with death rate. 
In summary, the major findings from this study contradicted what has been found in 
previous research in relation to antipsychotic medications increasing death rate for older adults 
with dementia. The current study looked at the frequency antipsychotic medications were taken 
throughout the week, in the categories of 1) none at all, 2) inconsistently throughout the week — 1 
to 6 days, and 3) consistently at seven days a week. This appears to be the first study to have 
done this, and results suggest through different forms of analyses that those taking antipsychotic 
medications as a PRN have an increased death rate, however those taking them 7 days a week 
have a lower death rate, when compared to those who are not taking these medications at all, 
both for those with and without dementia. 
Further research should be conducted to confirm and expand these findings. This may 
lead to a change in prescription and dispensing rates of antipsychotic medications. It may be that 
recommendations are made for physicians to stop prescribing these medications on an as needed 
basis (PRN), and actually encourage the prescribing of antipsychotics for older adults with 
dementia, and sometimes for those without. This may increase quality of life if it is found that 
taking these medications inconsistently is increasing other side effects, and expand life by using 
these medications regularly as a protective agent. 
Research Limitations 
Despite the contribution to the area of antipsychotic use in older adults with dementia, 
there are limitations to the current study. The most significant limitation is regarding factors 
related to the antipsychotic medications. Information regarding the specific type of antipsychotic 
medication participants were taking was unavailable, nor was it available for the class of 
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antipsychotic, conventional or atypical. This information may have helped further explain the 
unique findings of this study or enabled more detailed results regarding death rates in older 
adults taking these medications. 
The dosage of antipsychotic medication that people were taking was also not included in 
the dataset. This could provide information related to death rate that could also help further 
explain these unexpected results. For example, it may be that those individuals who were taking 
antipsychotic medications as a PRN were on a stronger single dose than those individuals who 
were taking it consistently throughout the week, leading to a higher risk of side effects and death. 
It may also be found in subsequent studies that the individuals who were taking antipsychotic 
medications as a PRN may have been closer to death to begin with, hence their inflated death 
rate, as disruptive behaviours naturally decline with more profound stages of illness so daily 
antipsychotics use may not have been necessary. In addition, other medications that participants 
were on were not included in the analysis, as it was out of the scope of this study. Future 
research may find that there is a correlation between higher death rate when people are taking an 
antipsychotic medication and another specific type of medication. 
Lastly, as the participants in this study were residents of CCC and LTC facilities, the 
results and potential prescription recommendations may not be fully attributable to community 
based older adults. There may be some unique factors related to older adults in residential care, 
such as severity of illness, comorbid illnesses, or age, that may attribute to these results, that 
would not be consistent for older adults living in the community. It would be beneficial for 
future research to see if the results from this study can be replicated with a large community 
based sample. 
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